Pressure BioSciences (PBIO) 10-Q 14 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 07, 2018
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830,656
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		1,565,082
Trading Symbol	PBIO
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 18,491	$ 81,033
Accounts receivable	526,090	206,848
Inventories, net of $139,700 reserve at June 30, 2018 and $179,600 at December 31, 2017	900,063	857,662
Prepaid expenses and other current assets	202,736	222,158
Total current assets	1,647,380	1,367,701
Intangible assets, net of amortization of $43,269 and $0, respectively	707,611	750,000
Investment in available-for-sale equity securities	17,991	19,825
Property and equipment, net	19,177	22,662
TOTAL ASSETS	2,392,159	2,160,188
CURRENT LIABILITIES
Accounts payable	697,961	589,263
Accrued employee compensation	427,625	368,700
Accrued professional fees and other	917,498	800,620
Other current liabilities	912,402	1,536,507
Deferred revenue	208,857	263,106
Revolving note payable		3,500,000
Related party convertible debt, net of debt discount of $0 and $31,372, respectively		259,762
Convertible debt, net of unamortized debt discounts of $547,582 and $401,856, respectively	3,222,167	8,028,014
Other debt, net of unamortized discounts of $25,982 and $48,194, respectively	703,130	1,379,863
Total current liabilities	7,089,640	16,725,835
LONG TERM LIABILITIES
Deferred revenue	45,990	57,149
TOTAL LIABILITIES	7,135,630	16,782,984
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 1,537,094 and 1,342,858 shares issued and outstanding on June 30, 2018 and December 31, 2017, respectively	15,371	13,429
Warrants to acquire common stock	17,450,717	9,878,513
Additional paid-in capital	37,747,441	30,833,549
Accumulated deficit	(59,958,064)	(55,349,299)
Total stockholders' deficit	(4,743,471)	(14,622,796)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	2,392,159	2,160,188
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	806	806
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	35	35
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	68	68
Series AA Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock	$ 52

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Inventories reserve	$ 139,700	$ 179,600
Amortization of intangible assets	43,269	0
Related party debt, net of debt discount	0	31,372
Convertible debt, current unamortized discounts	547,582	401,856
Other debt, unamortized discounts net	$ 25,982	$ 48,194
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	1,000,000	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	1,537,094	1,342,858
Common stock, shares outstanding	1,537,094	1,342,858
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	80,570	80,570
Convertible preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,458	3,458
Convertible preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	6,880	6,880
Convertible preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	5,195.4	0
Convertible preferred stock, shares outstanding	5,195.4	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue:
Total revenue	$ 638,773	$ 540,372	$ 1,249,547	$ 1,091,729
Costs and expenses:
Cost of products and services	270,046	287,299	594,835	523,296
Research and development	323,832	241,783	648,808	505,239
Selling and marketing	224,942	300,111	499,410	513,120
General and administrative	740,843	915,470	1,535,448	1,753,468
Total operating costs and expenses	1,559,663	1,744,663	3,278,501	3,295,123
Operating loss	(920,890)	(1,204,291)	(2,028,954)	(2,203,394)
Other expense:
Interest expense	(1,159,242)	(1,983,112)	(2,282,387)	(3,509,744)
Other expense	(9,582)	(80)	(14,312)	(7,108)
Gain on extinguishment of debt	471,612		475,897
Incentive shares/warrants	(663,130)	(186,802)	(663,130)	(186,802)
Change in fair value of derivative liabilities		2,790,525		(271,227)
Total other (expense) income	(1,360,342)	620,531	(2,483,932)	(3,974,881)
Net loss	(2,281,232)	(583,760)	(4,512,886)	(6,178,275)
Deemed dividend on down round feature	(213,012)		(213,012)
Deemed dividend on beneficial conversion feature	(10,532,291)		(10,532,291)
Preferred stock dividends	(95,879)		(95,879)
Net loss attributable to common stockholders	$ (13,122,414)	$ (583,760)	$ (15,354,068)	$ (6,178,275)
Basic and diluted net loss per share attributable to common stockholders	$ (9.20)	$ (0.54)	$ (11.01)	$ (5.83)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	1,426,698	1,077,529	1,395,187	1,059,250
Products, Services, Other [Member]
Revenue:
Total revenue	$ 618,418	$ 480,400	$ 1,203,662	$ 1,006,398
Grant Revenue [Member]
Revenue:
Total revenue	$ 20,355	$ 59,972	$ 45,885	$ 85,331

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Comprehensive Loss
Net loss	$ (2,281,232)	$ (583,760)	$ (4,512,886)	$ (6,178,275)
Other comprehensive loss
Unrealized income on marketable securities		6,190		6,190
Comprehensive loss	$ (2,281,232)	$ (577,570)	$ (4,512,886)	$ (6,172,085)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,512,886)	$ (6,178,275)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for debt extension	28,490	10,000
Depreciation and amortization	45,874	4,716
Accretion of interest and amortization of debt discount	986,155	2,922,265
Issuance of incentive shares and common stock warrants	663,130	186,802
Inventory reserve recovery	(39,900)
Gain on extinguishment of debt	(475,897)
Stock-based compensation expense	148,270	179,511
Amortization of third party fees paid in common stock and warrants		30,558
Shares issued with debt	7,800
Change in fair value of derivative liabilities		271,227
Impairment loss on investment	1,834	6,069
Changes in operating assets and liabilities:
Accounts receivable	(319,242)	(282,728)
Inventories	(2,501)	(226,204)
Prepaid expenses and other assets	19,422	82,193
Accounts payable	108,698	338,838
Accrued employee compensation	58,925	310,615
Deferred revenue and other accrued expenses	678,789	4,715
Net cash used in operating activities	(2,603,039)	(2,339,698)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment		(16,617)
Net cash used in investing activities		(16,617)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from revolving note payable	460,000	1,610,000
Net proceeds from warrant exercises		140,215
Net proceeds from Series AA convertible preferred stock	226,091
Net proceeds from convertible debt	3,242,950
Net proceeds from non-convertible debt - third party	952,501	1,987,752
Net proceeds from non-convertible debt - related party	102,100
Payments on convertible debt	(1,518,500)	(840,541)
Payments on non-convertible debt - related party	(52,100)
Payments on non-convertible debt	(872,545)	(478,141)
Net cash provided by financing activities	2,540,497	2,419,285
NET INCREASE (DECREASE) IN CASH	(62,542)	(62,970)
CASH AT BEGINNING OF YEAR	81,033	138,363
CASH AT END OF PERIOD	18,491	201,333
SUPPLEMENTAL INFORMATION
Interest paid in cash	525,979	173,243
Income taxes paid
NON CASH TRANSACTIONS:
Common stock issued in lieu of cash for interest	90,023
Common stock issued with debt	170,745	297,252
Discount from warrants issued with convertible debt	162,023	554,998
Discount from one-time interest	154,500	175,000
Unrealized gain from available-for-sale equity securities		6,190
Preferred stock dividends	95,879
Conversion of debt into preferred stock	12,688,634
Contingent beneficial conversion feature on convertible note	253,000
Deemed dividend-triggered down round feature	213,012
Deemed dividend-beneficial conversion feature	10,532,291
Derivative liability released upon warrant exercise		$ 49,327

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure BioSciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (45,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels - at controlled temperatures and specific time intervals - to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, and small molecules. Our laboratory instrument, the Barocycler®, and our internally developed consumables product line, including PULSE® (Pressure Used to Lyse Samples for Extraction) Tubes, other processing tubes, and application specific kits (which include consumable products and reagents) together make up our PCT Sample Preparation System, or PCT SPS. In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities and we cannot reasonably predict when operations will commence. Therefore, we do not have control of the subsidiary and did not consolidate in our financial statements. PBI Europe did not have any operations in the six months ended June 30, 2018 or in fiscal year 2017.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of June 30, 2018, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Notes 6 and 7. In addition we raised cash through debt financing after June 30, 2018 as described in Note 8. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.

Interim Financial Reporting

Interim Financial Reporting	6 Months Ended
	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Reporting	3) Interim Financial Reporting The accompanying unaudited consolidated balance sheet as of December 31, 2017, which was derived from audited financial statements, and the unaudited interim consolidated financial statements of Pressure BioSciences, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles” or “GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all material adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on April 2, 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4) Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Reclassifications Certain prior year amounts have been reclassified to conform to our current year presentation. Recent Accounting Standards In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires the recognition of assets and liabilities arising from lease transactions on the balance sheet and the disclosure of key information about leasing arrangements. Accordingly, a lessee will recognize a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Both the asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. Lessees will also be required to provide additional qualitative and quantitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. We will adopt ASC 842 effective January 1, 2019. We are currently in the process of evaluating the impact of the guidance on our consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The guidance is effective for interim and annual periods beginning after December 15, 2017, and early adoption is permitted. The Company early adopted the ASU 2016-18 on January 1, 2017. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business to provide additional guidance with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This ASU is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company early adopted the ASU 2016-18 on January 1, 2017 starting with its purchase of BaroFold assets. Effective January 1, 2018, the Company adopted ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The most significant impact to our consolidated financial statements relates to the recognition and measurement of equity investments at fair value with changes recognized in Net income. The amendment also updates certain presentation and disclosure requirements. The adoption of ASU 2016-01 did not have a material impact on the consolidated financial statements. The adoption of ASU 2016-01 is expected to increase volatility in net income as changes in the fair value of available-for-sale equity investments and changes in observable prices of equity investments without readily determinable fair values will be recorded in net income. Effective January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers, using the modified retrospective method. This guidance supersedes nearly all existing revenue recognition guidance under US GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company updated its accounting policy for the new standard based on a detailed review of its business and contracts. Based on the new guidance, the Company continues to recognize revenue at a point in time for the majority of its contracts with customers, which is generally when products are either shipped or delivered. Therefore, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. In July 2018, the FASB issued ASU 2018-07, Compensation- Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting as an amendment and update expanding the scope of Topic 718. The amendment specifies that Topic 718 now applies to all share-based payment transactions, even non-employee awards, in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. Under the new guidance, awards to nonemployees are measured on the grant date, rather than on the earlier of the performance commitment date or the date at which the nonemployee’s performance is complete. Also, the awards would be measured by estimating the fair value of the equity instruments to be issued, rather than the fair value of the goods or services received or the fair value of the equity instruments issued, whichever can be measured more reliably. In addition, entities may use the expected term to measure nonemployee awards or elect to use the contractual term as the expected term, on an award-by-award basis. The new guidance is effective for the Company in annual periods beginning after December 15, 2018, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact of this new guidance. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We currently record revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. In accordance with FASB ASC 840, Leases Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended June 30, Six Months Ended June 30, Primary geographical markets 2018 2017 2018 2017 North America 351 396 716 722 Europe 64 1 219 158 Asia 224 143 315 211 639 540 1,250 1,091 Three Months Ended June 30, Six Months Ended June 30, Major products/services lines 2018 2017 2018 2017 Hardware 397 347 817 743 Grants 20 60 45 85 Consumables 64 52 139 115 Contract research services 67 - 67 - Sample preparation accessories 47 39 96 74 Technical support/extended service contracts 22 26 50 43 Shipping and handling 16 11 28 21 Other 6 5 8 10 639 540 1,250 1,091 Three Months Ended June 30, Six Months Ended June 30, Timing of revenue recognition 2018 2017 2018 2017 Products transferred at a point in time 609 471 1,185 985 Products and services transferred over time 30 69 65 106 639 540 1,250 1,091 Contract balances In thousands of US dollars ($) June 30, 2018 December 31, 2017 Receivables, which are included in ‘Accounts Receivable’ 526 207 Contract liabilities (deferred revenue) 255 320 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. In thousands of US dollars ($) 2018 2019 2020 Total Extended warranty service 209 46 - 255 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2018 and 2017. For the Three Months Ended June 30, 2018 2017 Top Five Customers 54 % 60 % Federal Agencies 12 % 11 % For the Six Months Ended June 30, 2018 2017 Top Five Customers 38 % 42 % Federal Agencies 8 % 8 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2018 and December 31, 2017. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, 2018 December, 31, 2017 Top Five Customers 70 % 85 % Federal Agencies 11 % 1 % Product Supply CBM Industries (Taunton, MA) has recently become the manufacturer of the Barocycler® 2320EXT. CBM is ISO 13485:2003 and 9001:2008 Certified. CBM provides us with precision manufacturing services that include management support services to meet our specific application and operational requirements. Among the services provided by CBM to us are: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification At this time, we believe that outsourcing the manufacturing of our new Barocycler® 2320EXT to CBM is the most cost-effective method for us to obtain and maintain ISO Certified, CE and CSA Marked instruments. CBM’s close proximity to our South Easton, MA facility is a significant asset enabling interactions between our Engineering, R&D, and Manufacturing groups and their counterparts at CBM. CBM was instrumental in helping PBI achieve CE Marking on our Barocycler® 2320EXT, as announced on February 2, 2017. Although we currently manufacture and assemble the Barozyme HT48, Barocycler® HUB440, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility, we plan to take advantage of the established relationship with CBM and transfer manufacturing of the entire Barocycler® product line, future instruments, and other products to CBM. The Barocycler® NEP3229, launched in 2008, and manufactured by the BIT Group, will be phased out over the next several years and replaced by the new state-of-the-art Barocycler® HUB and Barozyme HT48 product lines. Investment in Available-For-Sale Equity Securities As of June 30, 2018, we held 100,250 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities” Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2018 and 2017: For the Three Months Ended For the Six Months Ended June 30, June 30, 2018 2017 2018 2017 Numerator: Net loss $ (2,281,232 ) $ (583,760 ) $ (4,512,886 ) $ (6,178,275 ) Deemed dividend on down round feature (213,012 ) - (213,012 ) - Deemed dividend on beneficial conversion feature (10,532,291 ) - (10,532,291 ) - Preferred stock dividends (95,879 ) - (95,879 ) - Net loss applicable to common shareholders $ (13,122,414 ) $ (583,760 ) $ (15,354,068 ) $ (6,178,275 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 1,426,698 1,077,529 1,395,187 1,059,250 Loss per common share – basic and diluted $ (9.20 ) $ (0.54 ) $ (11.01 ) $ (5.83 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series H2 Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of June 30, 2018 2017 Stock options 244,467 250,109 Convertible debt 346,133 827,560 Common stock warrants 6,263,607 890,047 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 28,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 117,367 Series K Convertible Preferred Stock 229,334 227,200 Series AA Convertible Preferred Stock 5,195,400 - 12,549,399 2,469,474 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $62,249 and $104,982 for the three months ended June 30, 2018 and 2017, respectively. The Company recognized stock-based compensation expense of $148,270 and $179,511 for the six months ended June 30, 2018 and 2017, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2018 2017 2018 2017 Research and development $ 15,649 $ 22,949 $ 31,148 $ 38,918 Selling and marketing 7,279 13,447 14,476 24,334 General and administrative 39,321 68,586 102,646 116,259 Total stock-based compensation expense $ 62,249 $ 104,982 $ 148,270 $ 179,511 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to convertible debentures and deferred revenue with carrying values that approximate fair value. The issuances of our convertible promissory notes and common stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible note. The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The adjusted BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. At present, these equity features of the convertible promissory notes have been recorded at a discount to the convertible notes that is substantially equal to the proceeds received. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2–Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Adoption of ASU 2017-11 The Company changed its method of accounting for the Debentures, Debenture Warrants and Series D Warrants through the early adoption of ASU 2017-11 during the year ended December 31, 2017 on a modified retrospective basis. Accordingly, the Company reclassified the warrant derivative and conversion option derivative liabilities to additional paid in capital on its January 1, 2017 consolidated balance sheets totaling approximately $2.6 million, reduced debt discount by approximately $0.9 million and recorded the cumulative effect of the adoption to the beginning balance of accumulated deficit of approximately $2.4 million. This resulted to an increase in stock warrants by $2.6 million and additional paid-in capital by $1.4 million. The following table provides a reconciliation of the warrant derivative liability, convertible debt, conversion option derivative liability, stock warrant, additional paid-in capital and accumulated deficit on the consolidated balance sheet as of December 31, 2016: Convertible debt, current portion Convertible debt, long term portion Warrant Derivative Liability Conversion Option Liability Warrants to acquire common stock Additional Paid-in Capital Accumulated deficit Balance, January 1, 2017 (Prior to adoption of ASU 2017-11) $ 4,005,702 $ 529,742 $ 1,685,108 $ 951,059 $ 6,325,102 $ 27,544,265 $ (42,264,190 ) Reclassified derivative liabilities and cumulative effect of adoption 769,316 154,152 (1,685,108 ) (951,059 ) 2,636,236 1,446,011 (2,369,548 ) Balance, January 1, 2017 (After adoption of ASU 2017-11) $ 4,775,018 $ 683,894 $ - $ - $ 8,961,338 $ 28,990,276 $ (44,633,738 ) The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Fair value measurements at June 30, 2018 using: June 30, 2018 Quoted prices in active markets (Level 1) Significant (Level 2) Significant (Level 3) Available-For-Sale Equity Securities 17,991 17,991 - - Total Financial Assets $ 17,991 $ 17,991 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017: Fair value measurements at December 31, 2017 using: December 31, 2017 Quoted markets Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 19,825 19,825 - - Total Financial Assets $ 19,825 $ 19,825 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5) Commitments and Contingencies Operating Leases Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $6,950 per month, on a lease extension, signed on December 29, 2017, that expires December 31, 2018, for our corporate office. We expanded our space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected in the current payments. We extended our lease for our space in Medford, MA to December 30, 2020. The lease requires monthly payments of $6,912.75 subject to annual cost of living increases. The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term. Rental costs are expensed as incurred. During the six months ended June 30, 2018 and 2017 we incurred $92,216 and $69,092 in rent expense, respectively for the use of our corporate office and research and development facilities. Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2018: 2018 $ 83,177 2019 82,953 2020 82,953 2021 - Thereafter - $ 249,083 Government Grants We received a $1.02 million NIH SBIR Phase II Grant in November 2014. Under the grant, the NIH has committed to pay the Company to develop a high-throughput, high pressure-based DNA Shearing System for Next Generation Sequencing and other genomic applications. In March 2018, we received an extension on the SBIR Phase II grant to utilize unused funds until November 30, 2018.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	6) Convertible Debt and Other Debt Conversion of Notes We issued 5,075.40 shares of our Series AA Convertible Preferred Stock in satisfaction of $12,688,634 of convertible promissory notes, Revolving Note and short-term loans issued: Debt converted to stock Current liabilities Convertible Debentures, face value $ 6,962,634 Revolving Note with interest 4,750,000 May 19, 2017 Promissory Note with interest 750,000 Other Notes with interest 226,000 Total debt converted in the second quarter of 2018 $ 12,688,634 Senior Secured Convertible Debentures and Warrants We entered into Subscription Agreements (the “ Subscription Agreement Purchaser Debentures Warrants Purchase Price The Company issued a principal aggregate amount of $6,962,634 in Debentures which includes a 10% original issue discount on the Purchase Price. The Debenture does not accrue any additional interest during the first year it is outstanding but accrues interest at a rate equal to 10% per annum for the second year it is outstanding. The Debenture has a maturity date of two years from issuance. The Debenture is convertible any time after its issuance date. The Purchaser has the right to convert the Debenture into shares of the Company’s common stock at a fixed conversion price equal to $8.40 per share, subject to applicable adjustments. In the second year that the Debenture is outstanding, any interest accrued shall be payable quarterly in either cash or common stock, at the Company’s discretion. In connection with the Debentures issued, the Company issued warrants exercisable into a total of 376,759 shares of our common stock. The Warrants issued in this transaction are immediately exercisable at an exercise price of $12.00 per share, subject to applicable adjustments including full ratchet anti-dilution if we issue any securities at a price lower than the exercise price then in effect. The Warrants have an expiration period of five years from the original issue date. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations and also include anti-dilution price protection for subsequent equity sales below the exercise price. On May 2, 2018, the Company entered into a Securities Purchase Agreement with an existing shareholder pursuant to which the Company sold an aggregate of 100 shares of Series AA Convertible Preferred Stock for an aggregate Purchase Price of $250,000. We issued to the shareholder a new warrant to purchase 100,000 shares of common stock with an exercise price of $3.50 per share. The Company, pursuant to a price protection provision triggered on May 2, 2018 with the sale of Series AA units, amended the Debentures and Warrants to purchase Common Stock held by the Debenture Holders entered into between July 22, 2015 and March 31, 2016 as first disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2015. The fair value of $207,899 relating to the reduction in exercise price was treated as a deemed dividend and recorded as a charge against additional paid-in capital within equity. The amended Debenture conversion price was exempt from revaluation because a beneficial conversion feature had already been recorded on the Debenture at issuance. Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days. In connection with the Subscription Agreement and Debenture, the Company entered into Security Agreements with the Purchasers whereby the Company agreed to grant to Purchasers an unconditional and continuing, first priority security interest in all of the assets and property of the Company to secure the prompt payment, performance and discharge in full of all of Company’s obligations under the Debentures, Warrants and the other Transaction Documents. On May 14 and June 11, 2018, the Company signed letter agreements with the Debenture holders as explained below that discharged all of the Company’s obligations within the Debenture Agreement. Conversion of Debentures On May 14, 2018, we entered into letter agreements (the “Letter Agreements”) with 22 investors (each a “Debenture Holder” and together the “Debenture Holders”) holding convertible debentures (collectively the “Debentures”) and warrants to purchase common stock (the “Debenture Warrants”) whereby the Debenture Holders agreed to convert a total of $6,220,500 in principal and original issue discount due them under the Debentures into 2,448.20 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Debenture Holders were also: (a) issued amended Debenture Warrants such that the exercise price will be $3.50 per share; and (b) issued a new warrant with an exercise price of $3.50 per share to purchase 2,448,200 shares of common stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversions). The Debenture Holders also agreed to waive any and all defaults or events of default by the Company with respect to any failure by the Company to comply with any covenants contained in the Debentures. The fair value of $29,865 relating to the adjustment in exercise price was treated as a loan modification and recorded as a gain toward the extinguishment of debt. On June 11, 2018, the Company entered into additional Letter Agreements with 15 Debenture Holders whereby the Debenture Holders agreed to convert a total of $742,134 in principal and original issue discount due them under the Debentures into 296.80 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Debenture Holders were also: (a) issued amended Debenture Warrants such that the exercise price will be $3.50 per share; and (b) issued a new warrant with an exercise price of $3.50 per share to purchase 296,800 shares of common stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversions). The Debenture Holders also agreed to waive any and all defaults or events of default by the Company with respect to any failure by the Company to comply with any covenants contained in the Debentures. The fair value of $3,155 relating to the adjustment in exercise price was treated as a loan modification and recorded as a gain toward the extinguishment of debt. In connection with the above Debenture conversions and cancellation of the debt term, the Company recorded the full amount of the remaining unamortized Debenture discounts of $157,908 as interest expense during the three months of June 30, 2018. The Company recorded $287,676 of the Debenture discounts during the six months ended June 30, 2018. On various dates for the six months ended June 30, 2018, the Company issued 25,243 shares of common stock based on the 10-day VWAP prior to quarter end to holders of the Debentures in payment of the quarterly interest accrued from the Debentures first anniversary date through December 31, 2017 for an aggregate amount of $95,121. We recognized a $5,101 gain on extinguishment of debt by calculating the difference of the shares valued on the issuance date and the amount of accrued interest through December 31, 2017. Other convertible notes The Company, pursuant to a price protection provision triggered on May 2, 2018 with the sale of Series AA units, amended the conversion price of a March 12, 2018 loan to $2.50 per share. The fair value of $253,000, limited to the face value of the loan, relating to the reset in the conversion price was recorded as a debt discount and amortized as interest expense over the remaining loan term. On various dates during the six months ended June 30, 2018, the Company issued convertible notes for net proceeds of $3,242,950 which contained varied terms and conditions as follows: a) maturity dates ranging from 3 to 12 months; b) interest rates that accrue per annum ranging from 5% to 12%; c) convertible to the Company’s common stock at issuance at a fixed rate of $7.50 or convertible at variable conversion rates either after 6 months after issuance or in the event of a default. Certain of these notes were issued with shares of common stock or warrants to purchase common stock that were fair valued at issuance dates. The aggregate relative fair value of $214,351 of the shares of common stock or warrants to purchase common stock issued with the notes was recorded as a debt discount and amortized over the term of the notes. We then computed the effective conversion price of the notes, noting that no beneficial conversion feature exists. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment as of June 30, 2018. The specific terms of the convertible notes and outstanding balances as of June 30, 2018 are listed in the tables below. Convertible Notes Inception Date Term Loan Amount Outstanding Balance with OID Original Issue Discount Interest Rate Conversion Price (Convertible at Inception Date) Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 30 months 1 $ 2,398,000 $ - 4 $ 218,000 2 10 % 3 $ 8.40 $ 388,532 $ 2,163,074 September 25, 2015 30 months 1 1,210,000 - 4 110,000 2 10 % 3 $ 8.40 185,956 1,022,052 October 2, 2015 30 months 1 165,000 - 4 15,000 2 10 % 3 $ 8.40 26,345 140,832 October 6, 2015 30 months 1 33,000 - 4 3,000 2 10 % 3 $ 8.40 5,168 26,721 October 14, 2015 30 months 1 55,000 - 4 5,000 2 10 % 3 $ 8.40 8,954 49,377 November 2, 2015 30 months 1 275,000 - 4 25,000 2 10 % 3 $ 8.40 43,079 222,723 November 10, 2015 30 months 1 55,000 - 4 5,000 2 10 % 3 $ 8.40 8,790 46,984 November 12, 2015 30 months 1 236,500 - 4 21,500 2 10 % 3 $ 8.40 38,518 212,399 November 20, 2015 30 months 1 220,000 - 4 20,000 2 10 % 3 $ 8.40 37,185 200,000 December 4, 2015 30 months 1 187,000 - 4 17,000 2 10 % 3 $ 8.40 37,352 170,000 December 11, 2015 30 months 1 396,000 - 4 36,000 2 10 % 3 $ 8.40 75,449 360,000 December 18, 2015 30 months 1 60,500 - 4 5,500 2 10 % 3 $ 8.40 11,714 55,000 December 31, 2015 30 months 1 110,000 - 4 10,000 2 10 % 3 $ 8.40 20,634 100,000 January 11, 2016 30 months 1 110,000 - 4 10,000 2 10 % 3 $ 8.40 24,966 80,034 January 20, 2016 30 months 1 55,000 - 4 5,000 2 10 % 3 $ 8.40 9,812 40,188 January 29, 2016 30 months 1 330,000 - 4 30,000 2 10 % 3 $ 8.40 60,887 239,113 February 26, 2016 30 months 1 220,000 - 4 20,000 2 10 % 3 $ 8.40 43,952 156,048 March 10, 2016 30 months 1 137,500 - 4 12,500 2 10 % 3 $ 8.40 18,260 106,740 March 18, 2016 30 months 1 396,000 - 4 36,000 2 10 % 3 $ 8.40 94,992 265,008 March 24, 2016 30 months 1 117,334 - 4 10,667 2 10 % 3 $ 8.40 15,427 91,240 March 31, 2016 30 months 1 195,670 - 4 17,788 2 10 % 3 $ 8.40 2,436 175,446 October 20, 2017 12 months 150,000 - - 5 % $ 7.50 7,500 - October 25, 2017 6 months 103,000 - - 12 % - 3,000 October 27, 2017 12 months 170,000 - - 5 % - 4,250 10,000 November 13, 2017 9 months 380,000 - 15,200 8 % $ 7.50 15,200 46,274 November 22, 2017 12 months 100,000 - 10,000 5 % - 2,000 - November 28, 2017 10 months 103,000 - 3,000 12 % - - - November 29, 2017 6 months 150,000 - - 15 % $ 7.50 - 15,200 November 30, 2017 3 months 50,000 - - 8 % $ 7.50 - - December 5, 2017 3 months 52,500 - - 10 % $ 7.50 2,500 - December 6, 2017 4 months 100,000 - - 10 % $ 7.50 - - December 11, 2017 6 months 130,000 - 1,500 5 % - 6,500 6,460 December 19, 2017 6 months 110,000 - 1,500 5 % - 5,500 5,775 December 28, 2017 6 months 55,000 - - 15 % $ 7.50 5,000 - December 29, 2017 12 months 105,000 - - 5 % - 5,000 - January 3, 2018 12 months 95,000 95,000 4,750 5 % - 2,000 - January 16, 2018 12 months 131,250 131,250 - - 6,250 - January 19, 2018 6 months 150,000 150,000 - 10 % $ 7.50 6,000 12,267 February 9, 2018 6 months 100,000 100,000 - 15 % $ 7.50 23,500 - February 15, 2018 6 months 100,000 100,000 - 15 % $ 7.50 9,000 10,474 March 12, 2018 6 months 85,000 85,000 1,150 5 % - 4,250 5,183 March 12, 2018 6 months 253,000 253,000 53,000 0 % - 28,722 April 11, 2018 6 months 100,000 100,000 4,000 15 % $ 7.50 20,000 7,218 April 23, 2018 6 months 103,000 103,000 - 12 % - 3,000 - April 24, 2018 9 months 77,000 77,000 - 12 % $ 7.50 2,000 - April 25, 2018 12 months 105,000 105,000 - 4 % $ 7.50 5,000 4,590 April 25, 2018 12 months 105,000 105,000 - 4 % $ 7.50 5,000 4,590 April 25, 2018 12 months 130,000 130,000 - 6 % $ 7.50 6,500 - April 26, 2018 12 months 65,000 65,000 6,500 5 % - 2,000 - May 9, 2018 12 months 250,000 250,000 - 10 % $ 7.50 12,500 26,466 May 11, 2018 6 months 161,250 161,250 11,250 15 % $ 7.50 10,000 - May 14, 2018 9 months 50,000 50,000 2,500 15 % $ 7.50 2,500 3,704 May 17, 2018 12 months 380,000 380,000 15,200 8 % $ 7.50 15,200 43,607 May 23, 2018 9 months 103,000 103,000 - 12 % - 3,000 - May 24, 2018 9 months 52,500 52,500 2,500 4 % - - 2,075 May 25, 2018 12 months 78,750 78,750 - 4 % $ 7.50 3,750 3,112 May 30, 2018 2 months 150,000 150,000 - 8 % $ 7.50 - 6,870 June 4, 2018 12 months 75,000 75,000 7,500 5 % - 2,000 3,869 June 8, 2018 6 months 50,000 50,000 2,500 15 % $ 7.50 2,500 3,271 June 12, 2018 6 months 100,000 100,000 - 5 % $ 7.50 5,000 - June 14, 2018 9 months 280,000 280,000 25,000 10 % - 5,000 17,573 June 16, 2018 9 months 130,000 130,000 - 5 % - - - June 16, 2018 6 months 110,000 110,000 - 5 % - - - June 26, 2018 3 months 150,000 150,000 - 15 % $ 7.50 - 20,242 June 28, 2018 6 months 50,000 50,000 - 15 % $ 7.50 - 10,518 $ 12,490,754 $ 3,769,750 $ 800,005 $ 1,343,858 $ 6,221,039 1. The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock. The Debenture holders signed letter agreements on May 14, 2018 and June 11, 2018 to waive default penalties relating to the maturity date. 2. The original issue discount is reflected in the first year. 3. The annual interest started accruing in the second year. 4. The Debentures were converted into Series AA Convertible Preferred Stock. Deferred finance fees included cash commissions amounting to $621,500 and the fair value of the 2,101,786 warrants issued to the placement agent amounting to $536,908. For the six months ended June 30, 2018, the Company recognized amortization expense related to the convertible debt discounts indicated above of $905,171. The unamortized debt discounts as of June 30, 2018 related to the convertible debentures and other convertible notes amounted to $547,582. Revolving Note Payable and May 19, 2017 Promissory Note On October 28, 2016, an accredited investor (the “ Investor Revolving Note Maturity Date Line of Credit Warrants The Revolving Note was amended on May 2, 2017 to increase the aggregate principal amount to $3,000,000, to issue 16,667 shares of our Common Stock to the Investor, to decrease the exercise price per share of the warrants to the lower of (i) $12.00 or (ii) the per share purchase price of the shares of our Common Stock sold in the Qualified Offering, and to change the references in the Revolving Note from “the six (6) month anniversary of October 28, 2016” to “July 25, 2017.” The fair value of the 16,667 shares issued of $149,018 was accounted for as a note discount and are amortized to interest expense over the life of the loan. We evaluated the accounting impact of the Revolving Note amendment and deemed that the amendment did not have a material impact on our consolidated financial statements. The Revolving Note was amended on August 18, 2017 to increase the aggregate principal amount to $3,500,000 with all other terms unchanged. The Revolving Note, previously amended, was further amended on January 30, 2018 to increase the aggregate principal amount to $4,000,000 with all other terms unchanged. In the event that a Qualified Offering had occurred after July 25, 2017, but prior to the Maturity Date, within seven (7) Business Days of the closing of the Qualified Offering, the Company was to pay a cash fee equal to five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering or, at the option of the Company, issue to the Holder a number of restricted shares of the Company’s common stock equal to (x) five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering divided by (y) the purchase price provided by the documents governing the Qualified Offering. A Qualified Offering Interest on the principal balance of the Revolving Note shall be paid in full on the Maturity Date, unless otherwise paid prior to the Maturity Date. Interest shall be assessed as follows: (i) a one-time interest of 10% on all principal amounts advanced prior to April 28, 2017; (ii) the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between April 28, 2017 and July 28, 2017; or (iii) both of the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between July 28, 2017 and October 28, 2017. Broker fees amounting to $336,500, the one-time interest of $400,000 and the relative fair value of the 333,334 warrants issued to the Investor amounting to $1,266,691 were recorded as debt discounts and amortized over the term of the revolving note. The unamortized debt discounts related to the Revolving Note were fully amortized as of December 31, 2017. The finance costs from advances after December 31, 2017 were charged to interest expense directly because the maturity date had passed. On May 19, 2017, we received a 45-day non-convertible loan of $630,000 from the Investor. The loan provided guaranteed interest of $63,000 and had an origination fee of $32,000. We paid a broker $31,500 in connection with this loan. The unamortized debt discount as of June 30, 2018 was zero. Conversion of October 26, 2016 Revolving Note and May 19, 2017 Promissory Note On June 11, 2018, the Company entered into a Letter Agreement with the Investor to convert a total of $5,500,000 in principal and interest due to the Investor pursuant to the Revolving Note and the May 19, 2017 promissory note into 2,200 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Company also amended the Line of Credit Warrants held by the Investor. The Company lowered the Line of Credit Warrants’ exercise price from $12.00 per share to $3.50 per share. The fair value of $82,904 relating to the reduction in exercise price was treated as a loan modification and recorded as a charge against the extinguishment of debt. The Company also issued a new warrant to the Investor with an exercise price of $3.50 per share to purchase 2,200,000 shares of common stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the conversion of a total of $5,500,000). In connection with the Letter Agreement, the Investor also waived $520,680 of interest and fees owed as of June 30, 2018. We recognized $520,680 as a gain on extinguishment of debt. The following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts, during 2018: 2018 Balance at January 1, $ 11,787,776 Issuance of convertible debt, face value 4,029,750 Deferred financing cost (326,800 ) Debt discount related to one-time interest charge (132,000 ) Contingent beneficial conversion feature on convertible note (253,000 ) Debt discount from warrants issued with debt (162,023 ) Debt discount from shares issued with the notes (170,745 ) Conversion of debt into equity (10,962,634 ) Payments (1,518,500 ) Accretion of interest and amortization of debt discount to interest expense through June 30, 930,343 Balance at June 30, 3,222,167 Less: current portion 3,222,167 Convertible debt, long-term portion $ - Other Notes In March 2018, we received non-convertible loans totaling $150,000 from private investors. The loans include one-year term and 10% guaranteed interest. We converted these loans into Series AA Units. See below. In April 2018, we received a non-convertible loan for $10,000 from a private investor. The loan includes a one-year term and 10% guaranteed interest. We converted this loan into Series AA Units. See below. On March 21, 2017, we received an eight-month, non-convertible loan of $170,000 from an accredited investor. The loan earns an annual interest rate of 10% and includes a 10% original issue discount. We also agreed to issue the investor 5,667 shares of restricted common stock. We recorded the fair value of the shares amounting to $35,079 as a debt discount that will be amortized to interest expense during the term of the loan. The loan still remains outstanding as of June 30, 2018 with a balance of $170,000. The lender extended the term to December 31, 2017 and further to March 31, 2018 in exchange for a total of 9,500 shares of common stock with a fair value of $28,490 recorded as interest expense. The lender further extended the term to September 30, 2018 in exchange for 7,200 shares yet to be issued. We fully amortized $52,079 of the original debt discount in the year ended December 31, 2017. On August 1, 2017, we signed a non-convertible installment loan with a lender. Under the agreement we received a loan of $75,000 with a weekly repayment of $3,500 until payment in full. The loan includes $18,750 representing an original issue discount, interest and fees resulting in a total payable of $93,750. The loan was paid off entirely as of June 30, 2018. On September 12, 2017, we received a 9-month non-convertible loan of $225,000 from a privately-held investment firm. The loan earns an annual interest rate of 10%. The Company paid total fees of $25,000 including original issue discount and other costs related to this loan. We agreed to issue 3,333 shares at closing. We recorded the fair value of the shares as a debt discount that will be amortized to interest expense during the term of the loan. We amortized the entire debt discount of $38,000 as of June 30, 2018. In the event of default and at the option of the holder, the loan is convertible into common stock at a 35% discount to the average of the two lowest daily volume weighted average closing stock price for the 20 trading days prior to conversion. The loan was paid off entirely as of June 30, 2018. In June 2018, we received a non-convertible loan of $15,000 from a private investor. The loan includes a one-year term and 10% guaranteed interest. Conversion of Non-Convertible Notes On June 11, 2018, the Company entered into Letter Agreements with certain private investors to convert a total of $176,000 in principal and interest due to the private investors pursuant to certain loan documents into 70.4 Series AA Units representing 70.4 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share and warrants to purchase 70,400 shares of common stock. Merchant Agreements We have signed various Merchant Agreements which entitle the lenders to our customer receipts. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The following table shows our Merchant Agreements as of June 30, 2018. Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Interest Rate Deferred Finance Fees September 29, 2017 75,000 102,000 $ - 1,200.00 15 % 1,500 October 25, 2017 110,000 153,890 - 1,539.00 15 % 8,800 December 7, 2017 160,000 212,800 - 1,251.76 25 % 5,799 December 12, 2017 160,000 212,800 - 1,251.76 15 % 5,258 February 27, 2018 110,000 147,400 - 921.25 25 % 1,650 April 11, 2018 140,000 187,600 96,503 1,275.00 13 % 2,800 May 11, 2018 180,000 243,000 151,542 1,518.75 25 % 2,599 May 15, 2018 180,000 244,800 156,067 1,530.00 15 % 3,600 June 29, 2018 140,000 190,400 140,000 1,269.33 25 % 2,100 $ 1,255,000 $ 1,694,690 $ 544,112 $ 34,106 We amortized $55,811 and $168,860 of debt discounts during the six months ended June 30, 2018 and 2017, respectively for all non-convertible notes. The total unamortized discount for all non-convertible notes as of June 30, 2018 was $25,982. Related Party Notes On March 14, 2018, we received a one-year, non-convertible loan of $50,000 from a related party who was a member of the Company’s Board of Directors. This loan is included in net proceeds from non-convertible debt in the Statement of Cash Flows. The amount of $50,000 was converted on June 11, 2018 into 20 shares of Series AA Convertible Preferred Stock and 20,000 warrants to purchase common stock. The $7,500 guaranteed interest on the loan was recorded as a debt discount and amortized over the term of the debt. The interest is outstanding as of June 30, 2018. On May 31, 2018, we received two short-term loans of $46,500 and $5,600 from two members of the Company’s Board of Directors, respectively. We repaid both loans in full during June 2018 and paid interest of $6,975. On June 11, 2018, the Company entered into a Letter Agreement with one non-employee member of the Board, to convert $50,000 in principal due to the board member pursuant to a certain loan document into 20 Series AA Units representing 20 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share and warrants to purchase 20,000 shares of common stock.

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Stockholders' Deficit	7) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K 12) 10,000 shares have been designated as Series AA Convertible Preferred Stock (“ Series AA As of June 30, 2018, there were no shares of Junior A, and Series A, B, C, and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2017 for the pertinent disclosures of preferred stock. Series AA Convertible Preferred Stock and Warrants On May 2, 2018, the Company entered into a Securities Purchase Agreement with an existing shareholder pursuant to which the Company sold an aggregate of 100 shares of Series AA Convertible Preferred Stock, each preferred share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share, for an aggregate Purchase Price of $250,000. Each share of Series AA Convertible Preferred Stock will receive a cumulative dividend at the annual rate of eight percent (8%) payable quarterly commencing on September 30, 2018 on those shares of Series AA Convertible Preferred Stock purchased from the Company. We issued to the shareholder a new warrant to purchase 100,000 shares of common stock with an exercise price of $3.50 per share. The Warrant will expire on the fifth-year anniversary after issuance. The exercise price is also subject to adjustment in the event that we issue any shares of common stock or common stock equivalents at a per share price that is lower than the exercise price for the Series AA Warrants then in effect. Upon any such issuance, subject to certain exceptions, the exercise price will be reduced to the per share price at which such shares of common stock or common stock equivalents are issued. On May 14, 2018, we entered into Letter Agreements with 22 Debenture Holders holding Debentures and Debenture Warrants whereby the Debenture Holders agreed to convert a total of $6,220,500 in principal and original issue discount due them under the Debentures into 2,448.20 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Debenture Holders were also: (a) issued amended Debenture Warrants such that the exercise price will be $3.50 per share; and (b) issued a new warrant with an exercise price of $3.50 per share to purchase 2,448,200 shares of common stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversions). On June 1, 2018, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to which the Company sold an aggregate of 20 shares of Series AA Convertible Preferred Stock, each preferred share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share, for an aggregate Purchase Price of $50,000. We issued to the shareholders a new warrant to purchase 20,000 shares of common stock with an exercise price of $3.50 per share. On June 11, 2018, the Company entered into additional Letter Agreements with 15 Debenture Holders whereby the Debenture Holders agreed to convert a total of $742,134 in principal and original issue discount due them under the Debentures into 296.80 shares of Series AA Convertible Preferred Stock with a conversion price of $2.50 per share. The Debenture Holders were also: (a) issued amended Debenture Warrants such that the exercise price will be $3.50 per share; and (b) issued a new warrant with an exercise price of $3.50 per share to purchase 296,800 shares of common stock (the number of shares of common stock issuable upon conversion of the Series AA Convertible Preferred Stock shares received as a result of the Debenture conversions). The issuances of our convertible preferred stock and common stock purchase warrants are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible preferred stock. We analyzed these warrants and determined that they were not considered derivatives and therefore recorded the aggregate relative fair value of $7,037,424 into equity relating to the 5,195,400 warrants and 11,000 broker warrants issued. The convertible preferred stock is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible preferred stock is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the preferred stock is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible preferred stock and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares of common stock the convertible preferred stock is converted into by its terms. The adjusted BCF value of $10,532,291 was accounted for as a deemed dividend within equity and was included in the earnings per share calculation. Stock Options and Warrants Our stockholders approved our amended 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,800,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards made under the Plan. Under the Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of June 30, 2018, options to acquire 32,605 shares were outstanding under the Plan. At the Company’s December 12, 2013 Special Meeting, the shareholders approved the 2013 Equity Incentive Plan (the “2013 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Under the 2013 Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of June 30, 2018, options to acquire 81,925 shares were outstanding under the Plan with 2,917,519 shares available for future grant under the 2013 Plan. On November 29, 2015 the Company’s Board of Directors adopted the 2015 Nonqualified Stock Option Plan (the “2015 Plan”) pursuant to which 5,000,000 shares of our common stock were reserved for issuance upon exercise of non-qualified stock options. Under the 2015 Plan, we may award non-qualified stock options in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of June 30, 2018, non-qualified options to acquire 129,937 shares were outstanding under the Plan. All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance. The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average Average Total Shares Price per share Shares Price per share Shares Exercisable Balance outstanding, 12/31/17 247,692 $ 10.95 899,542 $ 12.03 1,147,234 1,073,850 Granted - - 5,376,734 3.50 5,376,734 Exercised - - - - - Expired - - (12,669 ) 12.00 (12,669 ) Forfeited (3,225 ) 16.04 - - (3,225 ) Balance outstanding, 6/30/2018 244,467 $ 10.88 6,263,607 $ 3.58 6,508,074 6,460,810 Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $ 7.50 - $11.99 133,024 7.8 $ 8.63 96,160 7.4 $ 8.72 12.00 – 14.99 88,705 7.2 12.00 78,305 7.2 12.00 15.00 – 17.99 5,879 4.2 15.00 5,879 4.2 15.00 18.00 – 20.99 12,187 1.7 18.00 12,187 1.7 18.00 21.00 – 30.00 4,672 2.4 30.00 4,672 2.4 30.00 $ 7.50 - $30.00 244,467 7.1 $ 10.88 197,203 6.8 $ 11.29 As of June 30, 2018, total unrecognized compensation cost related to the unvested stock-based awards was $249,107, which is expected to be recognized over weighted average period of 1.45 years. The aggregate intrinsic value associated with the options outstanding and exercisable as of June 30, 2018 was zero. The aggregate intrinsic value associated with the warrants outstanding and exercisable as of June 30, 2018 was approximately $2.7 million. The loans from November 13, 2017 and May 17, 2018 included Warrants that contains a price protection provision such that if we issue a warrant with any term more favorable to the holder of such warrant that was not similarly provided in these loans, then we shall notify the lender of such additional or more favorable term and such term, shall become a part of the loan agreements. The fair value of the reduction in exercise price was recorded as a deemed dividend of $5,113 in additional paid in capital. The Company, pursuant to a price protection provision triggered on May 2, 2018 with the sale of Series AA units, amended the Debentures and Warrants to purchase Common Stock held by the Debenture Holders entered into between July 22, 2015 and March 31, 2016 as first disclosed in the Company’s Current Report on Form 8-K filed on July 28, 2015. The fair value of $207,899 relating to the reduction in exercise price was treated as a deemed dividend and recorded as a charge against additional paid-in capital within equity. The amended Debenture conversion price was exempt from revaluation because a beneficial conversion feature had already been recorded on the Debenture at issuance. Common Stock Issuances During the six months ended June 30, 2018, we issued to Debenture holders 25,243 shares of common stock for quarterly interest of $95,121 issued in stock in lieu of cash. Of the 25,243 shares issued, 1,092 shares were issued to members of the Company’s Board of Directors, who are also Debenture holders. On January 19, 2018, we received a six-month, convertible loan of $150,000 from an accredited investor. The loan earns a one-time interest of 10% and includes a 10% original issue discount. We also issued the investor 4,000 shares of restricted common stock with a relative fair value of $12,267 recorded as a debt discount to be amortized over the six-month term. The loan can be converted at any time into common stock at a conversion price of $7.50. On February 12, 2018, we received a six-month, convertible loan of $100,000 from an accredited investor. The loan earns a one-time interest of 10%. $50,000 of the proceeds were used to pay off the outstanding balance of a previous loan from this lender. The loan can be converted at any time into common stock at a conversion price of $7.50. We issued the investor 5,000 shares of restricted common stock with a relative fair value of $18,274 of which $10,474 was recorded as a debt discount to be amortized over the six-month term while $7,800 was recorded to interest expense immediately because it related to the previous loan paid off. On February 12, 2018, we issued 3,500 shares of restricted common stock to an accredited investor to extend the maturity date of our eight-month, non-convertible loan of $170,000 originated on March 21, 2017 to February 15, 2018. The accredited investor agreed to a further extension to March 31, 2018 in exchange for 3,500 shares of restricted common stock issued on March 27, 2018. The lender further extended the term to September 30, 2018 in exchange for 7,200 shares yet to be issued. The total fair value of $28,490 relating to these stock issuances were recorded as interest expense as compensation for the loan extensions. On March 12, 2018, we received a six-month, convertible loan of $253,000 from an accredited investor. The loan has an original issue discount of $53,000. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 6,750 shares of restricted common stock with a relative fair value of $28,722 recorded as a debt discount to be amortized over the six-month term. On April 2, 2018, we issued 1,150 shares of restricted common stock with a fair value of $5,183 to the lender in connection with the March 12, 2018 5% one-year, convertible loan of $85,000. The fair value of the stock was recorded as a debt discount to be amortized over the one-year term. On April 12, 2018, we received a 15% six-month, convertible loan of $100,000 from an accredited investor. The loan includes total costs of $24,000 representing guaranteed interest, an original issue discount and legal fees. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 2,000 shares of restricted common stock with a fair value of $7,218 recorded as a debt discount to be amortized over the six-month term. On April 25, 2018, we received a 4% one-year, convertible loan of $105,000 from an accredited investor. The note is convertible on issuance date at $7.50 per share and after 180 days to be 60% of the lowest trading price for the common stock during the 20-trading day period prior to conversion. The loan includes $5,000 in fees. We agreed to issue the investor 1,200 shares of restricted common stock with a fair value of $4,590 recorded as a debt discount to be amortized over the one-year term. On April 25, 2018, we received another 4% one-year, convertible loan of $105,000 from an accredited investor. The note is convertible on issuance date at $7.50 per share and after 180 days to be 60% of the lowest trading price for the common stock during the 20-trading day period prior to conversion. The loan includes $5,000 in fees. We agreed to issue the investor 1,200 shares of restricted common stock with a fair value of $4,590 recorded as a debt discount to be amortized over the one-year term. On May 9, 2018, we received a 10% six-month, convertible loan of $250,000 from an accredited investor. The loan includes total costs of $62,500 representing guaranteed interest, an original issue discount and legal fees. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 8,000 shares of restricted common stock with a fair value of $26,466 recorded as a debt discount to be amortized over the six-month term. On May 14, 2018, we received a 15% nine-month, convertible loan of $50,000 from an accredited investor. The loan includes total costs of $12,500 representing guaranteed interest, an original issue discount and legal fees. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 1,000 shares of restricted common stock with a fair value of $3,704 recorded as a debt discount to be amortized over the nine-month term. On May 24, 2018, we received a 4% one-year, convertible loan of $50,000 from an accredited investor. The loan includes an original issue discount of $2,500. The note is convertible on issuance date at $7.50 per share and after 180 days to be 60% of the lowest trading price for the common stock during the 20-trading day period prior to conversion. We agreed to issue the investor 600 shares of restricted common stock with a fair value of $2,075 recorded as a debt discount to be amortized over the one-year term. On May 25, 2018, we received a 4% one-year, convertible loan of $75,000 from an accredited investor. The loan includes legal fees of $3,750. The note is convertible on issuance date at $7.50 per share and after 180 days to be 60% of the lowest trading price for the common stock during the 20-trading day period prior to conversion. We agreed to issue the investor 900 shares of restricted common stock with a fair value of $3,112 recorded as a debt discount to be amortized over the one-year term. On May 30, 2018, we received an 8% two-month, convertible loan of $150,000 from an accredited investor. The loan includes guaranteed interest of $12,000. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 2,000 shares of restricted common stock with a fair value of $6,870 recorded as a debt discount to be amortized over the two-month term. On June 4, 2018, we received a 5% one-year, convertible loan of $75,000 from an accredited investor. The loan includes total costs of $9,500 representing an original issue discount and legal fees. The note is convertible after 180 days to be 60% of the lowest trading price for the common stock during the 20-trading day period prior to conversion. We agreed to issue the investor 1,360 shares of restricted common stock with a fair value of $3,869 recorded as a debt discount to be amortized over the one-year term. On June 8, 2018, we received a 15% 6-month, convertible loan of $50,000 from an accredited investor. The loan includes total costs of $12,500 representing guaranteed interest, an original issue discount and legal fees. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 1,000 shares of restricted common stock with a fair value of $3,271 recorded as a debt discount to be amortized over the 6-month term. On June 11, 2018, the Company entered into a Letter Agreement with an accredited investor in which we agreed to issue 110,833 additional shares of common stock at $2.50 per share to the investor. The fair value was recorded as other charge of $340,257. We also issued 110,833 additional warrants with an exercise price of $3.50 and an expiration period of five years from the original issue date. The fair value was recorded as other charges of $312,637. The Company also amended 29,167 Warrants held by the Investor. The Company lowered the Warrants’ exercise price from $15.00 per share to $3.50 per share. The fair value of $10,236 relating to the reduction in exercise price was treated as an equity modification and recorded as a charge to other expenses. On June 14, 2018, we received a 10% nine-month, convertible loan of $250,000 from an accredited investor. The loan includes total costs of $30,000 representing an original issue discount and legal fees. The note is convertible after 180 days to be 65% of the average of the two lowest trading prices for the common stock during the 25-trading day period prior to conversion. We agreed to issue the investor 5,000 shares of restricted common stock with a fair value of $17,573 recorded as a debt discount to be amortized over the nine-month term. On June 26, 2018, we received a 5% 3-month, convertible loan of $150,000 from an accredited investor. The loan includes total costs of $7,500 representing guaranteed interest. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 6,000 shares of restricted common stock with a fair value of $20,242 recorded as a debt discount to be amortized over the 3-month term. On June 28, 2018, we received a 5% 6-month, convertible loan of $50,000 from an accredited investor. The loan includes $2,500 monthly guaranteed interest. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 4,000 shares of restricted common stock with a fair value of $10,518 recorded as a debt discount to be amortized over the 6-month term.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	8) Subsequent Events On July 1, 2018, we signed a six-month agreement with a firm to provide consulting services. We issued 24,000 shares of restricted common stock at inception of contract. The stock’s fair value of $93,600 based on the trading stock price on contract date will be amortized to expense over 6 months in 2018. On July 2, 2018, we received a 4% one-year, convertible loan of $125,000 from an accredited investor. The note is convertible on issuance date at $7.50 per share and after 180 days to be 60% of the lowest trading price for the common stock during the 15-trading day period prior to conversion. The loan includes $6,250 in fees. We issued the investor 1,500 shares of restricted common stock with a fair value of $5,850 recorded as a debt discount to be amortized over the one-year term. On July 3, 2018, the Company entered into a Securities Purchase Agreement with several accredited investors pursuant to which the Company sold an aggregate of 148 shares of Series AA Convertible Preferred Stock, each preferred share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share, for an aggregate Purchase price of $370,000. We issued to the investors warrants to purchase an aggregate 148,000 shares of common stock with an exercise price of $3.50 per share. On July 5, 2018, we paid off the entire outstanding balance on our December 29, 2017 5% one-year, convertible loan of $95,000. On July 5, 2018, we signed a six-month agreement with a firm to provide consulting services. We are committed to pay the firm 24,000 shares of restricted common stock at inception of contract. The stock’s fair value of $79,920 based on the trading stock price on contract date will be amortized to expense over 6 months in 2018. On July 10, 2018, we received a 5% one-year, convertible loan of $95,000 from an accredited investor. The loan can be converted into common stock after 180 calendar days at a discount of 40% of the lowest trading price for the common stock during the 20-trading day period prior to conversion. The loan includes $6,750 in fees. On July 13, 2018, we paid off the entire outstanding balance on our June 12, 2018 5% one-month, convertible loan of $100,000. On July 13, 2018, we received a 12% nine-month, convertible loan of $103,000 from an accredited investor. The loan can be converted into common stock after 180 calendar days at a discount of 42% of the average of the lowest two trading prices for the common stock during the 15-trading day period prior to conversion. The loan includes $3,000 in fees. On July 16, 2018 we signed a Merchant Agreement with a lender. Under the agreement we received $180,000, of which approximately $103,450 was used to pay off the outstanding balance on a previous loan dated April 11, 2018 from this lender, in exchange for rights to all customer receipts until the lender is paid $246,600, which is collected at the rate of $1,790.00 per business day. The $66,600 imputed interest will be recorded as interest expense when paid each day. Fees of $3,600 were deducted from the initial advance. The payments were secured by second position rights to all customer receipts until the loan has been paid in full. We accounted for the Merchant Agreement as a secured loan under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. On July 17, 2018, we received a 15% three-month, convertible loan for $100,000 from an accredited investor. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 2,000 shares monthly over three months for a total of 6,000 shares of restricted common stock with a fair value of $16,944 that was recorded as a debt discount to be amortized over the three-month term. We issued the first installment of 2,000 shares already on July 17, 2018. On July 18, 2018, we paid $13,125 that was recorded as interest expense to a lender to postpone the loan conversion option to August 31, 2018 on the January 16, 2018 convertible note with face value of $131,250. On July 18, 2018, the Board of Directors approved the immediate termination of outstanding stock options (approximately 247,000 shares) held by current officers, employees and board members and the issuance of new stock options to the same holders with an exercise price of $3.40 per share equal to the closing market price on July 18, 2018 and an expiration date of July 18, 2028. The new stock options for board members will vest 1/12th per month for 12 months. The new stock options for officers and employees will vest 1/36th per month for 36 months. The compensation value created by the termination and issuance of new stock options, as determined under the Black Scholes method, was approximately $58,000 and under current accounting rules results in a non-cash expense in current and future periods not to exceed the vesting periods of the stock options. The Board of Directors also awarded 126,267 to officers, employees and board members separately based on the annual compensation committee recommendation. On July 19, 2018, we refinanced the January 19, 2018 10% one-year, convertible loan of $150,000 with an accredited investor. The refinanced loan will now be due on January 19, 2019. We paid $36,000 in interest and fees on the January 19, 2018 loan in connection with the refinancing. We agreed to issue the investor 4,500 shares of restricted common stock with a fair value of $15,350 recorded as a debt discount to be amortized over the one-year term. On July 26, 2018, we issued the monthly installment of 2,000 shares of restricted common stock to the lender for the June 26, 2018 loan. On July 27, 2018, we issued the monthly installment of 667 shares of restricted common stock to the lender for the June 27, 2018 loan. On July 30, 2018, we received a 6% one-year, convertible loan of $80,000 from an accredited investor. The note is convertible on issuance date at $7.50 per share and after 180 days to be 60% of the lowest trading price for the common stock during the 15-trading day period prior to conversion. The loan includes $4,000 in fees. On July 31, 2018, we refinanced the May 30, 2018 8% two-month, convertible loan of $150,000 with an accredited investor. The refinanced loan will now be due on October 31, 2018 and has 12% guaranteed interest. We paid $12,000 in interest and fees on the May 30, 2018 loan in connection with the refinancing. We issued the investor 2,000 shares of restricted common stock with a fair value of $6,578 recorded as a debt discount to be amortized over the three-month term. On August 2, 2018, we issued 3,154 shares of common stock based on the 10-day VWAP prior to quarter end to holders of the Debentures in payment of quarterly interest. On August 8, 2018, we refinanced the February 9, 2018 15% six-month, convertible loan of $100,000 with an accredited investor. The refinanced loan will now be due on February 8, 2019. The refinanced loan will now be due on February 8, 2019 and has a 5% monthly guaranteed interest rate. We paid $23,500 in interest and fees on the February 9, 2018 loan in connection with the refinancing. We agreed to issue the investor 1,300 shares of restricted common stock per month over the six-month term. The shares have a total fair value of $21,590 that will be recorded as a debt discount to be amortized over the six-month term. On August 8, 2018, the Company entered into a Securities Purchase Agreement with several accredited investors pursuant to which the Company sold an aggregate of 52 shares of Series AA Convertible Preferred Stock, each preferred share convertible into 1,000 shares of the Company’s common stock, par value $0.01 per share, for an aggregate Purchase price of $130,000. We issued to the investors warrants to purchase an aggregate 52,000 shares of common stock with an exercise price of $3.50 per share.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to our current year presentation.
Recent Accounting Standards	Recent Accounting Standards In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires the recognition of assets and liabilities arising from lease transactions on the balance sheet and the disclosure of key information about leasing arrangements. Accordingly, a lessee will recognize a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Both the asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. Lessees will also be required to provide additional qualitative and quantitative disclosures regarding the amount, timing and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. We will adopt ASC 842 effective January 1, 2019. We are currently in the process of evaluating the impact of the guidance on our consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The guidance is effective for interim and annual periods beginning after December 15, 2017, and early adoption is permitted. The Company early adopted the ASU 2016-18 on January 1, 2017. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business to provide additional guidance with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This ASU is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company early adopted the ASU 2016-18 on January 1, 2017 starting with its purchase of BaroFold assets. Effective January 1, 2018, the Company adopted ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The standard amends various aspects of the recognition, measurement, presentation, and disclosure of financial instruments. The most significant impact to our consolidated financial statements relates to the recognition and measurement of equity investments at fair value with changes recognized in Net income. The amendment also updates certain presentation and disclosure requirements. The adoption of ASU 2016-01 did not have a material impact on the consolidated financial statements. The adoption of ASU 2016-01 is expected to increase volatility in net income as changes in the fair value of available-for-sale equity investments and changes in observable prices of equity investments without readily determinable fair values will be recorded in net income. Effective January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers, using the modified retrospective method. This guidance supersedes nearly all existing revenue recognition guidance under US GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company updated its accounting policy for the new standard based on a detailed review of its business and contracts. Based on the new guidance, the Company continues to recognize revenue at a point in time for the majority of its contracts with customers, which is generally when products are either shipped or delivered. Therefore, the adoption of ASC 606 did not have a material impact on the consolidated financial statements. In July 2018, the FASB issued ASU 2018-07, Compensation- Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting as an amendment and update expanding the scope of Topic 718. The amendment specifies that Topic 718 now applies to all share-based payment transactions, even non-employee awards, in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. Under the new guidance, awards to nonemployees are measured on the grant date, rather than on the earlier of the performance commitment date or the date at which the nonemployee’s performance is complete. Also, the awards would be measured by estimating the fair value of the equity instruments to be issued, rather than the fair value of the goods or services received or the fair value of the equity instruments issued, whichever can be measured more reliably. In addition, entities may use the expected term to measure nonemployee awards or elect to use the contractual term as the expected term, on an award-by-award basis. The new guidance is effective for the Company in annual periods beginning after December 15, 2018, and interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the impact of this new guidance.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with FASB ASC 606, ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We currently record revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. In accordance with FASB ASC 840, Leases Revenue from government grants is recorded when expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended June 30, Six Months Ended June 30, Primary geographical markets 2018 2017 2018 2017 North America 351 396 716 722 Europe 64 1 219 158 Asia 224 143 315 211 639 540 1,250 1,091 Three Months Ended June 30, Six Months Ended June 30, Major products/services lines 2018 2017 2018 2017 Hardware 397 347 817 743 Grants 20 60 45 85 Consumables 64 52 139 115 Contract research services 67 - 67 - Sample preparation accessories 47 39 96 74 Technical support/extended service contracts 22 26 50 43 Shipping and handling 16 11 28 21 Other 6 5 8 10 639 540 1,250 1,091 Three Months Ended June 30, Six Months Ended June 30, Timing of revenue recognition 2018 2017 2018 2017 Products transferred at a point in time 609 471 1,185 985 Products and services transferred over time 30 69 65 106 639 540 1,250 1,091 Contract balances In thousands of US dollars ($) June 30, 2018 December 31, 2017 Receivables, which are included in ‘Accounts Receivable’ 526 207 Contract liabilities (deferred revenue) 255 320 Transaction price allocated to the remaining performance obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. In thousands of US dollars ($) 2018 2019 2020 Total Extended warranty service 209 46 - 255 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Use of Estimates	Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2018 and 2017. For the Three Months Ended June 30, 2018 2017 Top Five Customers 54 % 60 % Federal Agencies 12 % 11 % For the Six Months Ended June 30, 2018 2017 Top Five Customers 38 % 42 % Federal Agencies 8 % 8 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2018 and December 31, 2017. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, 2018 December, 31, 2017 Top Five Customers 70 % 85 % Federal Agencies 11 % 1 % Product Supply CBM Industries (Taunton, MA) has recently become the manufacturer of the Barocycler® 2320EXT. CBM is ISO 13485:2003 and 9001:2008 Certified. CBM provides us with precision manufacturing services that include management support services to meet our specific application and operational requirements. Among the services provided by CBM to us are: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification At this time, we believe that outsourcing the manufacturing of our new Barocycler® 2320EXT to CBM is the most cost-effective method for us to obtain and maintain ISO Certified, CE and CSA Marked instruments. CBM’s close proximity to our South Easton, MA facility is a significant asset enabling interactions between our Engineering, R&D, and Manufacturing groups and their counterparts at CBM. CBM was instrumental in helping PBI achieve CE Marking on our Barocycler® 2320EXT, as announced on February 2, 2017. Although we currently manufacture and assemble the Barozyme HT48, Barocycler® HUB440, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility, we plan to take advantage of the established relationship with CBM and transfer manufacturing of the entire Barocycler® product line, future instruments, and other products to CBM. The Barocycler® NEP3229, launched in 2008, and manufactured by the BIT Group, will be phased out over the next several years and replaced by the new state-of-the-art Barocycler® HUB and Barozyme HT48 product lines.
Investment in Available-For-Sale Equity Securities	Investment in Available-For-Sale Equity Securities As of June 30, 2018, we held 100,250 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”
Computation of Loss Per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2018 and 2017: For the Three Months Ended For the Six Months Ended June 30, June 30, 2018 2017 2018 2017 Numerator: Net loss $ (2,281,232 ) $ (583,760 ) $ (4,512,886 ) $ (6,178,275 ) Deemed dividend on down round feature (213,012 ) - (213,012 ) - Deemed dividend on beneficial conversion feature (10,532,291 ) - (10,532,291 ) - Preferred stock dividends (95,879 ) - (95,879 ) - Net loss applicable to common shareholders $ (13,122,414 ) $ (583,760 ) $ (15,354,068 ) $ (6,178,275 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 1,426,698 1,077,529 1,395,187 1,059,250 Loss per common share – basic and diluted $ (9.20 ) $ (0.54 ) $ (11.01 ) $ (5.83 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series H2 Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of June 30, 2018 2017 Stock options 244,467 250,109 Convertible debt 346,133 827,560 Common stock warrants 6,263,607 890,047 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 28,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 117,367 Series K Convertible Preferred Stock 229,334 227,200 Series AA Convertible Preferred Stock 5,195,400 - 12,549,399 2,469,474
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $62,249 and $104,982 for the three months ended June 30, 2018 and 2017, respectively. The Company recognized stock-based compensation expense of $148,270 and $179,511 for the six months ended June 30, 2018 and 2017, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2018 2017 2018 2017 Research and development $ 15,649 $ 22,949 $ 31,148 $ 38,918 Selling and marketing 7,279 13,447 14,476 24,334 General and administrative 39,321 68,586 102,646 116,259 Total stock-based compensation expense $ 62,249 $ 104,982 $ 148,270 $ 179,511
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to convertible debentures and deferred revenue with carrying values that approximate fair value. The issuances of our convertible promissory notes and common stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative, then it is measured at fair value using the Black Scholes Option Model and recorded as a liability on the balance sheet. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible note. The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The adjusted BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. At present, these equity features of the convertible promissory notes have been recorded at a discount to the convertible notes that is substantially equal to the proceeds received.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2–Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Adoption of ASU 2017-11 The Company changed its method of accounting for the Debentures, Debenture Warrants and Series D Warrants through the early adoption of ASU 2017-11 during the year ended December 31, 2017 on a modified retrospective basis. Accordingly, the Company reclassified the warrant derivative and conversion option derivative liabilities to additional paid in capital on its January 1, 2017 consolidated balance sheets totaling approximately $2.6 million, reduced debt discount by approximately $0.9 million and recorded the cumulative effect of the adoption to the beginning balance of accumulated deficit of approximately $2.4 million. This resulted to an increase in stock warrants by $2.6 million and additional paid-in capital by $1.4 million. The following table provides a reconciliation of the warrant derivative liability, convertible debt, conversion option derivative liability, stock warrant, additional paid-in capital and accumulated deficit on the consolidated balance sheet as of December 31, 2016: Convertible debt, current portion Convertible debt, long term portion Warrant Derivative Liability Conversion Option Liability Warrants to acquire common stock Additional Paid-in Capital Accumulated deficit Balance, January 1, 2017 (Prior to adoption of ASU 2017-11) $ 4,005,702 $ 529,742 $ 1,685,108 $ 951,059 $ 6,325,102 $ 27,544,265 $ (42,264,190 ) Reclassified derivative liabilities and cumulative effect of adoption 769,316 154,152 (1,685,108 ) (951,059 ) 2,636,236 1,446,011 (2,369,548 ) Balance, January 1, 2017 (After adoption of ASU 2017-11) $ 4,775,018 $ 683,894 $ - $ - $ 8,961,338 $ 28,990,276 $ (44,633,738 ) The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Fair value measurements at June 30, 2018 using: June 30, 2018 Quoted prices in active markets (Level 1) Significant (Level 2) Significant (Level 3) Available-For-Sale Equity Securities 17,991 17,991 - - Total Financial Assets $ 17,991 $ 17,991 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017: Fair value measurements at December 31, 2017 using: December 31, 2017 Quoted markets Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 19,825 19,825 - - Total Financial Assets $ 19,825 $ 19,825 $ - $ -

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. In thousands of US dollars ($) Three Months Ended June 30, Six Months Ended June 30, Primary geographical markets 2018 2017 2018 2017 North America 351 396 716 722 Europe 64 1 219 158 Asia 224 143 315 211 639 540 1,250 1,091 Three Months Ended June 30, Six Months Ended June 30, Major products/services lines 2018 2017 2018 2017 Hardware 397 347 817 743 Grants 20 60 45 85 Consumables 64 52 139 115 Contract research services 67 - 67 - Sample preparation accessories 47 39 96 74 Technical support/extended service contracts 22 26 50 43 Shipping and handling 16 11 28 21 Other 6 5 8 10 639 540 1,250 1,091 Three Months Ended June 30, Six Months Ended June 30, Timing of revenue recognition 2018 2017 2018 2017 Products transferred at a point in time 609 471 1,185 985 Products and services transferred over time 30 69 65 106 639 540 1,250 1,091
Schedule of Contract Balances	Contract balances In thousands of US dollars ($) June 30, 2018 December 31, 2017 Receivables, which are included in ‘Accounts Receivable’ 526 207 Contract liabilities (deferred revenue) 255 320
Schedule of Future Related to Performance Obligations	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. In thousands of US dollars ($) 2018 2019 2020 Total Extended warranty service 209 46 - 255
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2018 and 2017. For the Three Months Ended June 30, 2018 2017 Top Five Customers 54 % 60 % Federal Agencies 12 % 11 % For the Six Months Ended June 30, 2018 2017 Top Five Customers 38 % 42 % Federal Agencies 8 % 8 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2018 and December 31, 2017. The Top Five Customers category may include federal agency receivable balances if applicable. June 30, 2018 December, 31, 2017 Top Five Customers 70 % 85 % Federal Agencies 11 % 1 %
Schedule of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2018 and 2017: For the Three Months Ended For the Six Months Ended June 30, June 30, 2018 2017 2018 2017 Numerator: Net loss $ (2,281,232 ) $ (583,760 ) $ (4,512,886 ) $ (6,178,275 ) Deemed dividend on down round feature (213,012 ) - (213,012 ) - Deemed dividend on beneficial conversion feature (10,532,291 ) - (10,532,291 ) - Preferred stock dividends (95,879 ) - (95,879 ) - Net loss applicable to common shareholders $ (13,122,414 ) $ (583,760 ) $ (15,354,068 ) $ (6,178,275 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 1,426,698 1,077,529 1,395,187 1,059,250 Loss per common share – basic and diluted $ (9.20 ) $ (0.54 ) $ (11.01 ) $ (5.83 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series H2 Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. As of June 30, 2018 2017 Stock options 244,467 250,109 Convertible debt 346,133 827,560 Common stock warrants 6,263,607 890,047 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 28,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 117,367 Series K Convertible Preferred Stock 229,334 227,200 Series AA Convertible Preferred Stock 5,195,400 - 12,549,399 2,469,474
Schedule of Stock Based Compensation Expense	. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2018 2017 2018 2017 Research and development $ 15,649 $ 22,949 $ 31,148 $ 38,918 Selling and marketing 7,279 13,447 14,476 24,334 General and administrative 39,321 68,586 102,646 116,259 Total stock-based compensation expense $ 62,249 $ 104,982 $ 148,270 $ 179,511
Schedule of Reconciliation Related to Liabilities	The following table provides a reconciliation of the warrant derivative liability, convertible debt, conversion option derivative liability, stock warrant, additional paid-in capital and accumulated deficit on the consolidated balance sheet as of December 31, 2016: Convertible debt, current portion Convertible debt, long term portion Warrant Derivative Liability Conversion Option Liability Warrants to acquire common stock Additional Paid-in Capital Accumulated deficit Balance, January 1, 2017 (Prior to adoption of ASU 2017-11) $ 4,005,702 $ 529,742 $ 1,685,108 $ 951,059 $ 6,325,102 $ 27,544,265 $ (42,264,190 ) Reclassified derivative liabilities and cumulative effect of adoption 769,316 154,152 $ (1,685,108 ) (951,059 ) 2,636,236 1,446,011 (2,369,548 ) Balance, January 1, 2017 (After adoption of ASU 2017-11) $ 4,775,018 $ 683,894 $ - $ - $ 8,961,338 $ 28,990,276 $ (44,633,738 )
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Fair value measurements at June 30, 2018 using: June 30, 2018 Quoted prices in active markets (Level 1) Significant (Level 2) Significant (Level 3) Available-For-Sale Equity Securities 17,991 17,991 - - Total Financial Assets $ 17,991 $ 17,991 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017: Fair value measurements at December 31, 2017 using: December 31, 2017 Quoted markets Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 19,825 19,825 - - Total Financial Assets $ 19,825 $ 19,825 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2018: 2018 $ 83,177 2019 82,953 2020 82,953 2021 - Thereafter - $ 249,083

Convertible Debt and Other De18

Convertible Debt and Other Debt (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Debt converted to stock Current liabilities Convertible Debentures, face value $ 6,962,634 Revolving Note with interest 4,750,000 May 19, 2017 Promissory Note with interest 750,000 Other Notes with interest 226,000 Total debt converted in the second quarter of 2018 $ 12,688,634
Schedule of Convertible Debts and Outstanding Balances	Convertible Notes Inception Date Term Loan Amount Outstanding Balance with OID Original Issue Discount Interest Rate Conversion Price (Convertible at Inception Date) Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 30 months 1 $ 2,398,000 $ - 4 $ 218,000 2 10 % 3 $ 8.40 $ 388,532 $ 2,163,074 September 25, 2015 30 months 1 1,210,000 - 4 110,000 2 10 % 3 $ 8.40 185,956 1,022,052 October 2, 2015 30 months 1 165,000 - 4 15,000 2 10 % 3 $ 8.40 26,345 140,832 October 6, 2015 30 months 1 33,000 - 4 3,000 2 10 % 3 $ 8.40 5,168 26,721 October 14, 2015 30 months 1 55,000 - 4 5,000 2 10 % 3 $ 8.40 8,954 49,377 November 2, 2015 30 months 1 275,000 - 4 25,000 2 10 % 3 $ 8.40 43,079 222,723 November 10, 2015 30 months 1 55,000 - 4 5,000 2 10 % 3 $ 8.40 8,790 46,984 November 12, 2015 30 months 1 236,500 - 4 21,500 2 10 % 3 $ 8.40 38,518 212,399 November 20, 2015 30 months 1 220,000 - 4 20,000 2 10 % 3 $ 8.40 37,185 200,000 December 4, 2015 30 months 1 187,000 - 4 17,000 2 10 % 3 $ 8.40 37,352 170,000 December 11, 2015 30 months 1 396,000 - 4 36,000 2 10 % 3 $ 8.40 75,449 360,000 December 18, 2015 30 months 1 60,500 - 4 5,500 2 10 % 3 $ 8.40 11,714 55,000 December 31, 2015 30 months 1 110,000 - 4 10,000 2 10 % 3 $ 8.40 20,634 100,000 January 11, 2016 30 months 1 110,000 - 4 10,000 2 10 % 3 $ 8.40 24,966 80,034 January 20, 2016 30 months 1 55,000 - 4 5,000 2 10 % 3 $ 8.40 9,812 40,188 January 29, 2016 30 months 1 330,000 - 4 30,000 2 10 % 3 $ 8.40 60,887 239,113 February 26, 2016 30 months 1 220,000 - 4 20,000 2 10 % 3 $ 8.40 43,952 156,048 March 10, 2016 30 months 1 137,500 - 4 12,500 2 10 % 3 $ 8.40 18,260 106,740 March 18, 2016 30 months 1 396,000 - 4 36,000 2 10 % 3 $ 8.40 94,992 265,008 March 24, 2016 30 months 1 117,334 - 4 10,667 2 10 % 3 $ 8.40 15,427 91,240 March 31, 2016 30 months 1 195,670 - 4 17,788 2 10 % 3 $ 8.40 2,436 175,446 October 20, 2017 12 months 150,000 - - 5 % $ 7.50 7,500 - October 25, 2017 6 months 103,000 - - 12 % - 3,000 October 27, 2017 12 months 170,000 - - 5 % - 4,250 10,000 November 13, 2017 9 months 380,000 - 15,200 8 % $ 7.50 15,200 46,274 November 22, 2017 12 months 100,000 - 10,000 5 % - 2,000 - November 28, 2017 10 months 103,000 - 3,000 12 % - - - November 29, 2017 6 months 150,000 - - 15 % $ 7.50 - 15,200 November 30, 2017 3 months 50,000 - - 8 % $ 7.50 - - December 5, 2017 3 months 52,500 - - 10 % $ 7.50 2,500 - December 6, 2017 4 months 100,000 - - 10 % $ 7.50 - - December 11, 2017 6 months 130,000 - 1,500 5 % - 6,500 6,460 December 19, 2017 6 months 110,000 - 1,500 5 % - 5,500 5,775 December 28, 2017 6 months 55,000 - - 15 % $ 7.50 5,000 - December 29, 2017 12 months 105,000 - - 5 % - 5,000 - January 3, 2018 12 months 95,000 95,000 4,750 5 % - 2,000 - January 16, 2018 12 months 131,250 131,250 - - 6,250 - January 19, 2018 6 months 150,000 150,000 - 10 % $ 7.50 6,000 12,267 February 9, 2018 6 months 100,000 100,000 - 15 % $ 7.50 23,500 - February 15, 2018 6 months 100,000 100,000 - 15 % $ 7.50 9,000 10,474 March 12, 2018 6 months 85,000 85,000 1,150 5 % - 4,250 5,183 March 12, 2018 6 months 253,000 253,000 53,000 0 % - 28,722 April 11, 2018 6 months 100,000 100,000 4,000 15 % $ 7.50 20,000 7,218 April 23, 2018 6 months 103,000 103,000 - 12 % - 3,000 - April 24, 2018 9 months 77,000 77,000 - 12 % $ 7.50 2,000 - April 25, 2018 12 months 105,000 105,000 - 4 % $ 7.50 5,000 4,590 April 25, 2018 12 months 105,000 105,000 - 4 % $ 7.50 5,000 4,590 April 25, 2018 12 months 130,000 130,000 - 6 % $ 7.50 6,500 - April 26, 2018 12 months 65,000 65,000 6,500 5 % - 2,000 - May 9, 2018 12 months 250,000 250,000 - 10 % $ 7.50 12,500 26,466 May 11, 2018 6 months 161,250 161,250 11,250 15 % $ 7.50 10,000 - May 14, 2018 9 months 50,000 50,000 2,500 15 % $ 7.50 2,500 3,704 May 17, 2018 12 months 380,000 380,000 15,200 8 % $ 7.50 15,200 43,607 May 23, 2018 9 months 103,000 103,000 - 12 % - 3,000 - May 24, 2018 9 months 52,500 52,500 2,500 4 % - - 2,075 May 25, 2018 12 months 78,750 78,750 - 4 % $ 7.50 3,750 3,112 May 30, 2018 2 months 150,000 150,000 - 8 % $ 7.50 - 6,870 June 4, 2018 12 months 75,000 75,000 7,500 5 % - 2,000 3,869 June 8, 2018 6 months 50,000 50,000 2,500 15 % $ 7.50 2,500 3,271 June 12, 2018 6 months 100,000 100,000 - 5 % $ 7.50 5,000 - June 14, 2018 9 months 280,000 280,000 25,000 10 % - 5,000 17,573 June 16, 2018 9 months 130,000 130,000 - 5 % - - - June 16, 2018 6 months 110,000 110,000 - 5 % - - - June 26, 2018 3 months 150,000 150,000 - 15 % $ 7.50 - 20,242 June 28, 2018 6 months 50,000 50,000 - 15 % $ 7.50 - 10,518 $ 12,490,754 $ 3,769,750 $ 800,005 $ 1,343,858 $ 6,221,039 1. The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock. The Debenture holders signed letter agreements on May 14, 2018 and June 11, 2018 to waive default penalties relating to the maturity date. 2. The original issue discount is reflected in the first year. 3. The annual interest started accruing in the second year. 4. The Debentures were converted into Series AA Convertible Preferred Stock.
Summary of Changes in Convertible Debt, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts, during 2018: 2018 Balance at January 1, $ 11,787,776 Issuance of convertible debt, face value 4,029,750 Deferred financing cost (326,800 ) Debt discount related to one-time interest charge (132,000 ) Contingent beneficial conversion feature on convertible note (253,000 ) Debt discount from warrants issued with debt (162,023 ) Debt discount from shares issued with the notes (170,745 ) Conversion of debt into equity (10,962,634 ) Payments (1,518,500 ) Accretion of interest and amortization of debt discount to interest expense through June 30, 930,343 Balance at June 30, 3,222,167 Less: current portion 3,222,167 Convertible debt, long-term portion $ -
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of June 30, 2018. Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Interest Rate Deferred Finance Fees September 29, 2017 75,000 102,000 $ - 1,200.00 15 % 1,500 October 25, 2017 110,000 153,890 - 1,539.00 15 % 8,800 December 7, 2017 160,000 212,800 - 1,251.76 25 % 5,799 December 12, 2017 160,000 212,800 - 1,251.76 15 % 5,258 February 27, 2018 110,000 147,400 - 921.25 25 % 1,650 April 11, 2018 140,000 187,600 96,503 1275.00 13 % 2,800 May 11, 2018 180,000 243,000 151,542 1,518.75 25 % 2,599 May 15, 2018 180,000 244,800 156,067 1,530.00 15 % 3,600 June 29, 2018 140,000 190,400 140,000 1,269.33 25 % 2,100 $ 1,255,000 $ 1,694,690 $ 544,112 $ 34,106

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average Average Total Shares Price per share Shares Price per share Shares Exercisable Balance outstanding, 12/31/17 247,692 $ 10.95 899,542 $ 12.03 1,147,234 1,073,850 Granted - - 5,376,734 3.50 5,376,734 Exercised - - - - - Expired - - (12,669 ) 12.00 (12,669 ) Forfeited (3,225 ) 16.04 - - (3,225 ) Balance outstanding, 6/30/2018 244,467 $ 10.88 6,263,607 $ 3.58 6,508,074 6,460,810
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $ 7.50 - $11.99 133,024 7.8 $ 8.63 96,160 7.4 $ 8.72 12.00 – 14.99 88,705 7.2 12.00 78,305 7.2 12.00 15.00 – 17.99 5,879 4.2 15.00 5,879 4.2 15.00 18.00 – 20.99 12,187 1.7 18.00 12,187 1.7 18.00 21.00 – 30.00 4,672 2.4 30.00 4,672 2.4 30.00 $ 7.50 - $30.00 244,467 7.1 $ 10.88 197,203 6.8 $ 11.29

Business Overview, Liquidity 20

Business Overview, Liquidity and Management Plans (Details Narrative) - lb	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2015
Pounds per square inch	45,000
PBI Europe [Member]
Percentage of ownership interest		49.00%
Percentage of investment bank retaining		51.00%

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Impairment loss on investment			$ 1,834	$ 6,069
Forfeiture rate			5.00%
Stock-based compensation expense	$ 62,249	$ 104,982	$ 148,270	$ 179,511
Warrant and option derivative to additional paid in capital	2,600,000		2,600,000
Reduced debt discount	900,000		900,000
Cumulative accumulated deficit	2,400,000		2,400,000
Increase in stock warrant	2,600,000		2,600,000
Additional paid in capital			$ 1,400,000
Everest Investments Holdings S.A. [Member]
Sale of stock number of shares received			100,250
Fair value of investment	$ 18,000		$ 18,000
Shares closing price per share	$ 0.18		$ 0.18

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue	$ 639,000	$ 540,000	$ 1,250,000	$ 1,091,000
Hardware [Member]
Revenue	397,000	347,000	817,000	743,000
Grants [Member]
Revenue	20,000	60,000	45,000	85,000
Consumables [Member]
Revenue	64,000	52,000	139,000	115,000
Contract Research Services [Member]
Revenue	67,000		67,000
Sample Preparation Accessories [Member]
Revenue	47,000	39,000	96,000	74,000
Technical Support/Extended Service Contracts [Member]
Revenue	22,000	26,000	50,000	43,000
Shipping and Handling [Member]
Revenue	16,000	11,000	28,000	21,000
Others [Member]
Revenue	6,000	5,000	8,000	10,000
Products Transferred at a Point in Time [Member]
Revenue	609,000	471,000	1,185,000	985,000
Products and Services Transferred Over Time [Member]
Revenue	30,000	69,000	65,000	106,000
North America [Member]
Revenue	351,000	396,000	716,000	722,000
Europe [Member]
Revenue	64,000	1,000	219,000	158,000
Asia [Member]
Revenue	$ 224,000	$ 143,000	$ 315,000	$ 211,000

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Schedule of Contract Balances (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Receivables, which are included in 'Accounts Receivable'	$ 526,000	$ 207,000
Contract liabilities (deferred revenue)	$ 255,000	$ 320,000

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Schedule of Future Related to Performance Obligations (Details)	Jun. 30, 2018USD ($)
Extended warranty service	$ 255,000
2018 [Member]
Extended warranty service	209,000
2019 [Member]
Extended warranty service	46,000
2020 [Member]
Extended warranty service

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Schedule of Customer Concentration Risk Percentage (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Top Five Customers [Member] | Revenue [Member]
Concentration credit risk percentage	54.00%	60.00%	38.00%	42.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration credit risk percentage			70.00%		85.00%
Federal Agencies [Member] | Revenue [Member]
Concentration credit risk percentage	12.00%	11.00%	8.00%	8.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration credit risk percentage			11.00%		1.00%

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Schedule of Computation of Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accounting Policies [Abstract]
Net loss	$ (2,281,232)	$ (583,760)	$ (4,512,886)	$ (6,178,275)
Deemed dividend on down round feature	(213,012)		(213,012)
Deemed dividend on beneficial conversion feature	10,532,291		10,532,291
Preferred stock dividends	(95,879)		(95,879)
Net loss applicable to common shareholders	$ (13,122,414)	$ (583,760)	$ (15,354,068)	$ (6,178,275)
Weighted average common stock shares outstanding	1,426,698	1,077,529	1,395,187	1,059,250
Loss per common share - basic and diluted	$ (9.20)	$ (0.54)	$ (11.01)	$ (5.83)

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Total potentially dilutive shares	12,549,399	2,469,474
Stock Options [Member]
Total potentially dilutive shares	244,467	250,109
Convertible Debt [Member]
Total potentially dilutive shares	346,133	827,560
Common Stock Warrants [Member]
Total potentially dilutive shares	6,263,607	890,047
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	26,857	28,857
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	115,267	117,367
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	229,334	227,200
Series AA Convertible Preferred Stock [Member]
Total potentially dilutive shares	5,195,400

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Schedule of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Total stock-based compensation expense	$ 62,249	$ 104,982	$ 148,270	$ 179,511
Research and Development [Member]
Total stock-based compensation expense	15,649	22,949	31,148	38,918
Selling and Marketing [Member]
Total stock-based compensation expense	7,279	13,447	14,476	24,334
General and Administrative [Member]
Total stock-based compensation expense	$ 39,321	$ 68,586	$ 102,646	$ 116,259

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Schedule of Reconciliation Related to Liabilities (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Additional Paid-in Capital [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	$ 27,544,265
Reclassified derivative liabilities and cumulative effect of adoption	1,446,011
Balance, January 1, 2017 (After adoption of ASU 2017-11)	28,990,276
Accumulated Deficit [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	(42,264,190)
Reclassified derivative liabilities and cumulative effect of adoption	(2,369,548)
Balance, January 1, 2017 (After adoption of ASU 2017-11)	(44,633,738)
Convertible Debt, Current Portion [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	4,005,702
Reclassified derivative liabilities and cumulative effect of adoption	769,316
Balance, January 1, 2017 (After adoption of ASU 2017-11)	4,775,018
Convertible Debt, Long Term Portion [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	529,742
Reclassified derivative liabilities and cumulative effect of adoption	154,152
Balance, January 1, 2017 (After adoption of ASU 2017-11)	683,894
Warrant Derivative Liability [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	1,685,108
Reclassified derivative liabilities and cumulative effect of adoption	(1,685,108)
Balance, January 1, 2017 (After adoption of ASU 2017-11)
Conversion Option Liability [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	951,059
Reclassified derivative liabilities and cumulative effect of adoption	(951,059)
Balance, January 1, 2017 (After adoption of ASU 2017-11)
Warrants to Acquire Common Stock [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	6,325,102
Reclassified derivative liabilities and cumulative effect of adoption	2,636,236
Balance, January 1, 2017 (After adoption of ASU 2017-11)	$ 8,961,338

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Total Financial Assets	$ 17,991	$ 19,825
Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	17,991	19,825
Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Available-For-Sale Equity Securities [Member]
Total Financial Assets	17,991	19,825
Available-For-Sale Equity Securities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	17,991	19,825
Available-For-Sale Equity Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Available-For-Sale Equity Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets

Commitments and Contingencies31

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 29, 2017	Jun. 30, 2018	Jun. 30, 2017	Nov. 30, 2014
Rental expenses		$ 92,216	$ 69,092
Lease expire date		Dec. 30, 2020
Lease monthly payments		$ 6,913
Lease expiration term		The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term.
NIH SBIR Phase II [Member]
Grants receivable				$ 1,020,000
Corporate Office [Member]
Rental expenses	$ 6,950
Lease expire date	Dec. 31, 2018

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Jun. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 83,177
2,019	82,953
2,020	82,953
2,021
Thereafter
Total minimum payments required	$ 249,083

Convertible Debt and Other De33

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Jun. 11, 2018	May 31, 2018	May 14, 2018	May 02, 2018	May 02, 2018	Mar. 27, 2018	Mar. 14, 2018	Mar. 12, 2018	Feb. 12, 2018	Sep. 12, 2017	Aug. 02, 2017	Jul. 25, 2017	May 19, 2017	May 02, 2017	Mar. 21, 2017	Apr. 30, 2018	Mar. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Feb. 15, 2018	Dec. 31, 2017	Jun. 01, 2018	Jan. 30, 2018	Aug. 18, 2017	Oct. 28, 2016
Debt conversion into common stock shares																					25,243
Debt principal amount																		$ 4,029,750			$ 4,029,750
Debt conversion price per share																		$ 7.50			$ 7.50
Warrant exercise price per share	$ 3.50
Warrant to purchase shares of common stock	110,833
Warrants rights description																					Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days.
Gain on extinguishment of debt																		$ 471,612			$ 475,897			$ 5,101
Interest expense																		157,908
Debenture discounts																					287,676
Accrued interest, debt																								95,121
Proceeds from convertible notes																					3,242,950
Amortization of debt discount																					129,768
Unamortized debt discount																		547,582			547,582			401,856
Proceeds from revolving note payable																					460,000	1,610,000		2,070,000
Origination fee amount																		34,106			34,106
Interest expense																		$ 1,159,242		$ 1,983,112	2,282,387	3,509,744
Other Convertible Notes [Member]
Amortization of debt discount																					214,351
Revolving Note [Member]
Debt principal amount																										$ 4,000,000	$ 3,500,000
Fair value of warrant																					333,334
Fees and commission																					336,500
One-time interest amount																					$ 400,000
Revolving Note [Member] | Prior to April 28, 2017 [Member]
Percentage of annual interest rates																		10.00%			10.00%
Revolving Note [Member] | April 28, 2017 And July 28, 2017 [Member]
Percentage of annual interest rates																		4.00%			4.00%
Revolving Note [Member] | July 28, 2017 And October 28, 2017 [Member]
Percentage of annual interest rates																		4.00%			4.00%
Non-Convertible Loan [Member]
Debt conversion into common stock shares	20
Debt conversion amount	$ 50,000
Convertible debentures term							1 year
Warrant to purchase shares of common stock	20,000
Amortization of debt discount																					$ 7,500
Proceeds from loan							$ 50,000
Non-Convertible Loan [Member] | Privately-Held Investment Firm [Member]
Percentage of annual interest rates										10.00%
Convertible debentures term										9 months
Amortization of debt discount																					$ 38,000
Unamortized debt discount										$ 25,000							$ 10,161		$ 10,161
Number of shares issued										3,333
Fees and commission										$ 25,000
Proceeds from loan										$ 225,000
Debt converted into common stock, percentage																					35.00%
Minimum [Member] | Convertible Notes [Member]
Percentage of annual interest rates																		5.00%			5.00%
Convertible debentures term																					3 months
Maximum [Member] | Convertible Notes [Member]
Percentage of annual interest rates																		12.00%			12.00%
Convertible debentures term																					12 months
Investor [Member] | Revolving Note [Member]
Amortization of debt discount																					$ 1,266,691
Private Investor [Member] | Non-Convertible Loan [Member]
Percentage of annual interest rates																		10.00%			10.00%
Convertible debentures term													45 days								1 year
Fees and commission													$ 31,500
One-time interest amount													63,000
Proceeds from loan													630,000
Origination fee amount													$ 32,000
Loan amount																		$ 15,000			$ 15,000
Private Investors [Member] | Non-Convertible Loans [Member]
Percentage of annual interest rates																10.00%	10.00%		10.00%
Convertible debentures term																1 year	1 year
Proceeds from loan																$ 10,000	$ 150,000
Accredited Investor [Memeber]
Convertible debentures term									8 months
Number of restricted stock issued during period						3,500			3,500
Accredited Investor [Memeber] | Non-Convertible Loan [Member]
Debt principal amount																		170,000			170,000
Percentage of annual interest rates															10.00%
Interest expense																							$ 28,490
Amortization of debt discount															$ 35,079									$ 52,079
Unamortized debt discount																		0			0
Number of shares issued																			9,500
Proceeds from loan															$ 170,000								$ 170,000
Interest expense																			$ 28,490
Original issue of discount percentage															10.00%
Number of restricted stock issued during period															5,667
Lender [Member] | Non-Convertible Installment Loan [Member]
Fees and commission											$ 93,750
Proceeds from loan											75,000
Repayment of debt											3,500
Lender [Member] | Non-Convertible Installment Loan [Member]
Unamortized debt discount											$ 18,750
Board of Directors [Member] | Short-term Loan One [Member]
Proceeds from loan		$ 46,500
Interest expense		6,975
Board of Directors [Member] | Short-term Loan Two [Member]
Proceeds from loan		5,600
Interest expense		$ 6,975
September 30, 2018 | Accredited Investor [Memeber]
Amortization of debt discount																					7,200
September 30, 2018 | Accredited Investor [Memeber] | Non-Convertible Loan [Member]
Number of shares issued															7,200
Placement Agent [Member] | Other Convertible Notes [Member]
Amortization of debt discount																					905,171
Cash commissions																					621,500
Fair value of warrant																					2,101,786
Gross proceeds from warrants																					536,908
Unamortized debt discount																		$ 547,582			$ 547,582
Investor [Member]
Warrant to purchase shares of common stock	29,167
Investor [Member] | Revolving Note [Member]
Issuance of warrants to purchase of common stock shares																												20,834
Warrant exercise price per share														$ 12														$ 12
Promissory note aggregate principal amount																												$ 2,000,000
Advance pursuant to revolving note																												$ 3,500,000
Increase in debt principal amount														$ 3,000,000
Number of shares issued														16,667
Debt instrument description														the per share purchase price of the shares of our Common Stock sold in the Qualified Offering, and to change the references in the Revolving Note from "the six (6) month anniversary of October 28, 2016" to "July 25, 2017."
Shares issued during period, value														$ 149,018
Investor [Member] | Maximum [Member] | Revolving Note [Member]
Issuance of warrants to purchase of common stock shares																												291,667
Warrant exercise price per share																												$ 12
Advance pursuant to revolving note																												$ 250,000
Investor [Member] | Maximum [Member] | Revolving Note [Member] | 15 Day Period [Member]
Advance pursuant to revolving note																												250,000
Investor [Member] | Maximum [Member] | Revolving Note [Member] | 30 Day Period [Member]
Advance pursuant to revolving note																												$ 500,000
Holder [Member]
Percentage of outstanding principal amount of debenture												5.00%
Equity ownership, percentage												5.00%
Gross proceeds of purchase consideration												$ 7,000,000
Subscription Agreement [Member] | Individuals [Member] | July 23, 2015 and March 31, 2016 [Member]
Percentage of warrants to purchase shares of common stock																		50.00%			50.00%
Purchase warrants price amount																					$ 6,329,549
Debt principal amount																		$ 6,962,634			$ 6,962,634
Percentage of debt original issue discount on purchase price																					10.00%
Percentage of annual interest rates																		10.00%			10.00%
Convertible debentures term																					2 years
Debt conversion price per share																		$ 8.40			$ 8.40
Issuance of warrants to purchase of common stock shares																		376,759			376,759
Warrants expiration period																					5 years
Warrant exercise price per share																		$ 12			$ 12
Securities Purchase Agreement [Member]
Warrant exercise price per share				$ 3.50	$ 3.50
Sale of stock				100
Sale of stock amount				$ 250,000
Warrant to purchase shares of common stock				100,000	100,000
Securities Purchase Agreement [Member] | New Warrant [Member]
Warrant exercise price per share				$ 3.50	$ 3.50																				$ 3.50
Warrant to purchase shares of common stock				100,000	100,000																				20,000
Letter Agreements [Member]
Gain on extinguishment of debt			$ 29,865
Letter Agreements [Member] | Debenture Warrants [Member]
Debt conversion price per share			$ 3.50
Issuance of warrants to purchase of common stock shares			2,448,200
Letter Agreements [Member] | New Warrant [Member]
Debt conversion price per share			$ 3.50
Letter Agreements [Member] | 22 Investors [Member]
Debt conversion amount			$ 6,220,500
Letter Agreements [Member] | Private Investors [Member]
Debt conversion into common stock shares	70.4
Debt conversion amount	$ 176,000
Debt conversion price per share	$ 2.50
Warrant to purchase shares of common stock	70,400
Letter Agreements [Member] | One Non-Employee [Member]
Debt conversion into common stock shares	20
Debt conversion amount	$ 50,000
Debt conversion price per share	$ 2.50
Warrant to purchase shares of common stock	20,000
Additional Letter Agreements [Member]
Gain on extinguishment of debt	$ 3,155
Additional Letter Agreements [Member] | Debenture Warrants [Member]
Warrant exercise price per share	$ 3.50
Additional Letter Agreements [Member] | New Warrant [Member]
Issuance of warrants to purchase of common stock shares	296,800
Warrant exercise price per share	$ 3.50
Additional Letter Agreements [Member] | 15 Debenture Holders [Member]
Debt conversion amount	$ 742,134
Letter Agreement [Member]
Debt conversion into common stock shares	296.80
Debt conversion amount	$ 742,134
Gain on extinguishment of debt																			520,680
Interest expense																			$ 520,680
Letter Agreement [Member] | Minimum [Member]
Warrant exercise price per share	$ 3.50
Letter Agreement [Member] | Maximum [Member]
Warrant exercise price per share	$ 12
Letter Agreement [Member] | New Warrant [Member]
Issuance of warrants to purchase of common stock shares	2,200,000
Warrant exercise price per share	$ 3.50		$ 3.50
Warrant to purchase shares of common stock	296,800		2,448,200
Letter Agreement [Member] | Investor [Member]
Debt conversion amount	$ 5,500,000
Merchant Agreement [Member]
Amortization of debt discount																					$ 55,811	$ 168,860
Unamortized debt discount																		$ 25,982			$ 25,982
Series AA Convertible Preferred Stock [Member]
Debt conversion into common stock shares																					5,075.40
Debt conversion amount								$ 147,791													$ 12,688,634
Debt conversion price per share								$ 2.50
Fair value of other convertible notes								$ 253,000
Series AA Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]
Sale of stock					100
Sale of stock amount					$ 250,000
Series AA Convertible Preferred Stock [Member] | Letter Agreements [Member]
Debt conversion into common stock shares			2,448.20
Debt conversion price per share			$ 2.50
Series AA Convertible Preferred Stock [Member] | Additional Letter Agreements [Member]
Debt conversion into common stock shares	296.80
Debt conversion price per share	$ 2.50
Series AA Convertible Preferred Stock [Member] | Letter Agreement [Member]
Debt conversion into common stock shares	2,200		2,448.20
Debt conversion amount			$ 6,220,500
Debt conversion price per share	$ 2.50		$ 2.50
Debt extinguishment	$ 82,904
Series AA Units [Member]
Debt conversion price per share				$ 2.50	$ 2.50
Reduction in exercise price amount					$ 207,899
Reduction in conversion price, amount					$ 3,631,470

Convertible Debt and Other De34

Convertible Debt and Other Debt - Schedule of Convertible Debt (Details)	Jun. 30, 2018USD ($)
Convertible debt	$ 12,688,634
Convertible Debentures, face value [Member]
Convertible debt	6,962,634
Revolving Note with Interest [Member]
Convertible debt	4,750,000
May 19, 2017 Promissory Note with Interest [Member]
Convertible debt	750,000
Other Notes with Interest [Member]
Convertible debt	$ 226,000

Convertible Debt and Other De35

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details)	6 Months Ended
	Jun. 30, 2018USD ($)$ / shares
Loan Amount	$ 4,029,750
Outstanding Balance with OID	$ 12,688,634
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 34,106
Discount related to Fair value of conversion feature and warrants	10,532,291
Convertible Notes [Member]
Loan Amount	12,490,754
Outstanding Balance with OID	3,769,750
Original Issue Discount	800,005
Deferred Finance Fees	1,343,858
Discount related to Fair value of conversion feature and warrants	$ 6,221,039
Convertible Notes [Member] | Convertible Debt [Member]
Inception Date	Jul. 22, 2015
Term	30 months	[1]
Loan Amount	$ 2,398,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 218,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 388,532
Discount related to Fair value of conversion feature and warrants	$ 2,163,074
Convertible Notes [Member] | Convertible Debt Two [Member]
Inception Date	Sep. 25, 2015
Term	30 months	[1]
Loan Amount	$ 1,210,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 110,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 185,956
Discount related to Fair value of conversion feature and warrants	$ 1,022,052
Convertible Notes [Member] | Convertible Debt Three [Member]
Inception Date	Oct. 2, 2015
Term	30 months	[1]
Loan Amount	$ 165,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 15,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 26,345
Discount related to Fair value of conversion feature and warrants	$ 140,832
Convertible Notes [Member] | Convertible Debt Four [Member]
Inception Date	Oct. 6, 2015
Term	30 months	[1]
Loan Amount	$ 33,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 3,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 5,168
Discount related to Fair value of conversion feature and warrants	$ 26,721
Convertible Notes [Member] | Convertible Debt Five [Member]
Inception Date	Oct. 14, 2015
Term	30 months	[1]
Loan Amount	$ 55,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 5,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 8,954
Discount related to Fair value of conversion feature and warrants	$ 49,377
Convertible Notes [Member] | Convertible Debt Six [Member]
Inception Date	Nov. 2, 2015
Term	30 months	[1]
Loan Amount	$ 275,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 25,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 43,079
Discount related to Fair value of conversion feature and warrants	$ 222,723
Convertible Notes [Member] | Convertible Debt Seven [Member]
Inception Date	Nov. 10, 2015
Term	30 months	[1]
Loan Amount	$ 55,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 5,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 8,790
Discount related to Fair value of conversion feature and warrants	$ 46,984
Convertible Notes [Member] | Convertible Debt Eight [Member]
Inception Date	Nov. 12, 2015
Term	30 months	[1]
Loan Amount	$ 236,500
Outstanding Balance with OID		[2]
Original Issue Discount	$ 21,500	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 38,518
Discount related to Fair value of conversion feature and warrants	$ 212,399
Convertible Notes [Member] | Convertible Debt Nine [Member]
Inception Date	Nov. 20, 2015
Term	30 months	[1]
Loan Amount	$ 220,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 20,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 37,185
Discount related to Fair value of conversion feature and warrants	$ 200,000
Convertible Notes [Member] | Convertible Debt Ten [Member]
Inception Date	Dec. 4, 2015
Term	30 months	[1]
Loan Amount	$ 187,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 17,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 37,352
Discount related to Fair value of conversion feature and warrants	$ 170,000
Convertible Notes [Member] | Convertible Debt Eleven [Member]
Inception Date	Dec. 11, 2015
Term	30 months	[1]
Loan Amount	$ 396,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 36,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 75,449
Discount related to Fair value of conversion feature and warrants	$ 360,000
Convertible Notes [Member] | Convertible Debt Twelve [Member]
Inception Date	Dec. 18, 2015
Term	30 months	[1]
Loan Amount	$ 60,500
Outstanding Balance with OID		[2]
Original Issue Discount	$ 5,500	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 11,714
Discount related to Fair value of conversion feature and warrants	$ 55,000
Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Inception Date	Dec. 31, 2015
Term	30 months	[1]
Loan Amount	$ 110,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 10,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 20,634
Discount related to Fair value of conversion feature and warrants	$ 100,000
Convertible Notes [Member] | Convertible Debt Fourteen [Member]
Inception Date	Jan. 11, 2016
Term	30 months	[1]
Loan Amount	$ 110,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 10,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 24,966
Discount related to Fair value of conversion feature and warrants	$ 80,034
Convertible Notes [Member] | Convertible Debt Fifteen [Member]
Inception Date	Jan. 20, 2016
Term	30 months	[1]
Loan Amount	$ 55,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 5,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 9,812
Discount related to Fair value of conversion feature and warrants	$ 40,188
Convertible Notes [Member] | Convertible Debt Sixteen [Member]
Inception Date	Jan. 29, 2016
Term	30 months	[1]
Loan Amount	$ 330,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 30,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 60,887
Discount related to Fair value of conversion feature and warrants	$ 239,113
Convertible Notes [Member] | Convertible Debt Seventeen [Member]
Inception Date	Feb. 26, 2016
Term	30 months	[1]
Loan Amount	$ 220,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 20,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 43,952
Discount related to Fair value of conversion feature and warrants	$ 156,048
Convertible Notes [Member] | Convertible Debt Eighteen [Member]
Inception Date	Mar. 10, 2016
Term	30 months	[1]
Loan Amount	$ 137,500
Outstanding Balance with OID		[2]
Original Issue Discount	$ 12,500	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 18,260
Discount related to Fair value of conversion feature and warrants	$ 106,740
Convertible Notes [Member] | Convertible Debt Nineteen [Member]
Inception Date	Mar. 18, 2016
Term	30 months	[1]
Loan Amount	$ 396,000
Outstanding Balance with OID		[2]
Original Issue Discount	$ 36,000	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 94,992
Discount related to Fair value of conversion feature and warrants	$ 265,008
Convertible Notes [Member] | Convertible Debt Twenty [Member]
Inception Date	Mar. 24, 2016
Term	30 months	[1]
Loan Amount	$ 117,334
Outstanding Balance with OID		[2]
Original Issue Discount	$ 10,667	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 15,427
Discount related to Fair value of conversion feature and warrants	$ 91,240
Convertible Notes [Member] | Convertible Debt Twenty One [Member]
Inception Date	Mar. 31, 2016
Term	30 months	[1]
Loan Amount	$ 195,670
Outstanding Balance with OID		[2]
Original Issue Discount	$ 17,788	[3]
Interest Rate	10.00%	[4]
Conversion Price (Convertible at Inception Date) | $ / shares	$ 8.40
Deferred Finance Fees	$ 2,436
Discount related to Fair value of conversion feature and warrants	$ 175,446
Convertible Notes [Member] | Convertible Debt Twenty Two [Member]
Inception Date	Oct. 20, 2017
Term	12 months
Loan Amount	$ 150,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 7,500
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Twenty Three [Member]
Inception Date	Oct. 25, 2017
Term	6 months
Loan Amount	$ 103,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	12.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 3,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Twenty Four [Member]
Inception Date	Oct. 27, 2017
Term	12 months
Loan Amount	$ 170,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 4,250
Discount related to Fair value of conversion feature and warrants	$ 10,000
Convertible Notes [Member] | Convertible Debt Twenty Five [Member]
Inception Date	Nov. 13, 2017
Term	9 months
Loan Amount	$ 380,000
Outstanding Balance with OID
Original Issue Discount	$ 15,200
Interest Rate	8.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 15,200
Discount related to Fair value of conversion feature and warrants	$ 46,274
Convertible Notes [Member] | Convertible Debt Twenty Six [Member]
Inception Date	Nov. 22, 2017
Term	12 months
Loan Amount	$ 100,000
Outstanding Balance with OID
Original Issue Discount	$ 10,000
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 2,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Twenty Seven [Member]
Inception Date	Nov. 28, 2017
Term	10 months
Loan Amount	$ 103,000
Outstanding Balance with OID
Original Issue Discount	$ 3,000
Interest Rate	12.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Twenty Eight [Member]
Inception Date	Nov. 29, 2017
Term	6 months
Loan Amount	$ 150,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants	$ 15,200
Convertible Notes [Member] | Convertible Debt Twenty Nine [Member]
Inception Date	Nov. 30, 2017
Term	3 months
Loan Amount	$ 50,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	8.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty [Member]
Inception Date	Dec. 5, 2017
Term	3 months
Loan Amount	$ 52,500
Outstanding Balance with OID
Original Issue Discount
Interest Rate	10.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 2,500
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty One [Member]
Inception Date	Dec. 6, 2017
Term	4 months
Loan Amount	$ 100,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	10.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Two [Member]
Inception Date	Dec. 11, 2017
Term	6 months
Loan Amount	$ 130,000
Outstanding Balance with OID
Original Issue Discount	$ 1,500
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 6,500
Discount related to Fair value of conversion feature and warrants	$ 6,460
Convertible Notes [Member] | Convertible Debt Thirty Three [Member]
Inception Date	Dec. 19, 2017
Term	6 months
Loan Amount	$ 110,000
Outstanding Balance with OID
Original Issue Discount	$ 1,500
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 5,500
Discount related to Fair value of conversion feature and warrants	$ 5,775
Convertible Notes [Member] | Convertible Debt Thirty Four [Member]
Inception Date	Dec. 28, 2017
Term	6 months
Loan Amount	$ 55,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 5,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Five [Member]
Inception Date	Dec. 29, 2017
Term	12 months
Loan Amount	$ 105,000
Outstanding Balance with OID
Original Issue Discount
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 5,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Six [Member]
Inception Date	Jan. 3, 2018
Term	12 months
Loan Amount	$ 95,000
Outstanding Balance with OID	95,000
Original Issue Discount	$ 4,750
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 2,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Seven [Member]
Inception Date	Jan. 16, 2018
Term	12 months
Loan Amount	$ 131,250
Outstanding Balance with OID	131,250
Original Issue Discount
Interest Rate
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 6,250
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Eight [Member]
Inception Date	Jan. 19, 2018
Term	6 months
Loan Amount	$ 150,000
Outstanding Balance with OID	150,000
Original Issue Discount
Interest Rate	10.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 6,000
Discount related to Fair value of conversion feature and warrants	$ 12,267
Convertible Notes [Member] | Convertible Debt Thirty Nine [Member]
Inception Date	Feb. 9, 2018
Term	6 months
Loan Amount	$ 100,000
Outstanding Balance with OID	100,000
Original Issue Discount
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 23,500
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Forty [Member]
Inception Date	Feb. 15, 2018
Term	6 months
Loan Amount	$ 100,000
Outstanding Balance with OID	100,000
Original Issue Discount
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 9,000
Discount related to Fair value of conversion feature and warrants	$ 10,474
Convertible Notes [Member] | Convertible Debt Forty One [Member]
Inception Date	Mar. 12, 2018
Term	6 months
Loan Amount	$ 85,000
Outstanding Balance with OID	85,000
Original Issue Discount	$ 1,150
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 4,250
Discount related to Fair value of conversion feature and warrants	$ 5,183
Convertible Notes [Member] | Convertible Debt Forty Two [Member]
Inception Date	Mar. 12, 2018
Term	6 months
Loan Amount	$ 253,000
Outstanding Balance with OID	253,000
Original Issue Discount	$ 53,000
Interest Rate	0.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants	$ 28,722
Convertible Notes [Member] | Convertible Debt Forty Three [Member]
Inception Date	Apr. 11, 2018
Term	6 months
Loan Amount	$ 100,000
Outstanding Balance with OID	100,000
Original Issue Discount	$ 4,000
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 20,000
Discount related to Fair value of conversion feature and warrants	$ 7,218
Convertible Notes [Member] | Convertible Debt Forty four [Member]
Inception Date	Apr. 23, 2018
Term	6 months
Loan Amount	$ 103,000
Outstanding Balance with OID	103,000
Original Issue Discount
Interest Rate	12.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 3,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Forty Five [Member]
Inception Date	Apr. 24, 2018
Term	9 months
Loan Amount	$ 77,000
Outstanding Balance with OID	77,000
Original Issue Discount
Interest Rate	12.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 2,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Forty Six [Member]
Inception Date	Apr. 25, 2018
Term	12 months
Loan Amount	$ 105,000
Outstanding Balance with OID	105,000
Original Issue Discount
Interest Rate	4.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 5,000
Discount related to Fair value of conversion feature and warrants	$ 4,590
Convertible Notes [Member] | Convertible Debt Forty Seven [Member]
Inception Date	Apr. 25, 2018
Term	12 months
Loan Amount	$ 105,000
Outstanding Balance with OID	105,000
Original Issue Discount
Interest Rate	4.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 5,000
Discount related to Fair value of conversion feature and warrants	$ 4,590
Convertible Notes [Member] | Convertible Debt Forty Eight [Member]
Inception Date	Apr. 25, 2018
Term	12 months
Loan Amount	$ 130,000
Outstanding Balance with OID	130,000
Original Issue Discount
Interest Rate	6.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 6,500
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Forty Nine [Member]
Inception Date	Apr. 26, 2018
Term	12 months
Loan Amount	$ 65,000
Outstanding Balance with OID	65,000
Original Issue Discount	$ 6,500
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 2,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Fifty [Member]
Inception Date	May 9, 2018
Term	12 months
Loan Amount	$ 250,000
Outstanding Balance with OID	250,000
Original Issue Discount
Interest Rate	10.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 12,500
Discount related to Fair value of conversion feature and warrants	$ 26,466
Convertible Notes [Member] | Convertible Debt Fifty One [Member]
Inception Date	May 11, 2018
Term	6 months
Loan Amount	$ 161,250
Outstanding Balance with OID	161,250
Original Issue Discount	$ 11,250
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 10,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Fifty Two [Member]
Inception Date	May 14, 2018
Term	9 months
Loan Amount	$ 50,000
Outstanding Balance with OID	50,000
Original Issue Discount	$ 2,500
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 2,500
Discount related to Fair value of conversion feature and warrants	$ 3,704
Convertible Notes [Member] | Convertible Debt Fifty Three [Member]
Inception Date	May 17, 2018
Term	12 months
Loan Amount	$ 380,000
Outstanding Balance with OID	380,000
Original Issue Discount	$ 15,200
Interest Rate	8.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 15,200
Discount related to Fair value of conversion feature and warrants	$ 43,607
Convertible Notes [Member] | Convertible Debt Fifty Four [Member]
Inception Date	May 23, 2018
Term	9 months
Loan Amount	$ 103,000
Outstanding Balance with OID	103,000
Original Issue Discount
Interest Rate	12.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 3,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Fifty Five [Member]
Inception Date	May 24, 2018
Term	9 months
Loan Amount	$ 52,500
Outstanding Balance with OID	52,500
Original Issue Discount	$ 2,500
Interest Rate	4.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants	$ 2,075
Convertible Notes [Member] | Convertible Debt Fifty Six [Member]
Inception Date	May 25, 2018
Term	12 months
Loan Amount	$ 78,750
Outstanding Balance with OID	78,750
Original Issue Discount
Interest Rate	4.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 3,750
Discount related to Fair value of conversion feature and warrants	$ 3,112
Convertible Notes [Member] | Convertible Debt Fifty Seven [Member]
Inception Date	May 30, 2018
Term	2 months
Loan Amount	$ 150,000
Outstanding Balance with OID	150,000
Original Issue Discount
Interest Rate	8.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants	$ 6,870
Convertible Notes [Member] | Convertible Debt Fifty Eight [Member]
Inception Date	Jun. 4, 2018
Term	12 months
Loan Amount	$ 75,000
Outstanding Balance with OID	75,000
Original Issue Discount	$ 7,500
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 2,000
Discount related to Fair value of conversion feature and warrants	$ 3,869
Convertible Notes [Member] | Convertible Debt Fifty Nine [Member]
Inception Date	Jun. 8, 2018
Term	6 months
Loan Amount	$ 50,000
Outstanding Balance with OID	50,000
Original Issue Discount	$ 2,500
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 2,500
Discount related to Fair value of conversion feature and warrants	$ 3,271
Convertible Notes [Member] | Convertible Debt Sixty [Member]
Inception Date	Jun. 12, 2018
Term	6 months
Loan Amount	$ 100,000
Outstanding Balance with OID	100,000
Original Issue Discount
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees	$ 5,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Sixty One [Member]
Inception Date	Jun. 14, 2018
Term	9 months
Loan Amount	$ 280,000
Outstanding Balance with OID	280,000
Original Issue Discount	$ 25,000
Interest Rate	10.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees	$ 5,000
Discount related to Fair value of conversion feature and warrants	$ 17,573
Convertible Notes [Member] | Convertible Debt Sixty Two [Member]
Inception Date	Jun. 16, 2018
Term	9 months
Loan Amount	$ 130,000
Outstanding Balance with OID	130,000
Original Issue Discount
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Sixty Three [Member]
Inception Date	Jun. 16, 2018
Term	6 months
Loan Amount	$ 110,000
Outstanding Balance with OID	110,000
Original Issue Discount
Interest Rate	5.00%
Conversion Price (Convertible at Inception Date) | $ / shares
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Sixty Four [Member]
Inception Date	Jun. 26, 2018
Term	3 months
Loan Amount	$ 150,000
Outstanding Balance with OID	150,000
Original Issue Discount
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants	$ 20,242
Convertible Notes [Member] | Convertible Debt Sixty Five [Member]
Inception Date	Jun. 28, 2018
Term	6 months
Loan Amount	$ 50,000
Outstanding Balance with OID	50,000
Original Issue Discount
Interest Rate	15.00%
Conversion Price (Convertible at Inception Date) | $ / shares	$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants	$ 10,518
[1]	The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock. The July 22, 2015 Debentures of $3,773,000 is currently past due as of March 19, 2018. The affected Debenture holders signed letter agreements on May 15, 2018 to waive default penalties relating to the maturity date.
[2]	The Debentures were converted into Series AA Convertible Preferred Stock.
[3]	The original issue discount is reflected in the first year.
[4]	The annual interest starts accruing in the second year.

Convertible Debt and Other De36

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)	Jul. 22, 2015
Debt Disclosure [Abstract]
Debt maturity description	The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock.

Convertible Debt and Other De37

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discounts (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Debt Disclosure [Abstract]
Balance at January 1,	$ 11,787,776
Issuance of convertible debt, face value	4,029,750
Deferred financing cost	(326,800)
Debt discount related to one-time interest charge	(132,000)
Contingent beneficial conversion feature on convertible note	253,000
Debt discount from warrants issued with debt	(162,023)
Debt discount from shares issued with the notes	(170,745)
Conversion of debt into equity	(10,962,504)
Payments	(1,518,500)	$ (840,541)
Accretion of interest and amortization of debt discount to interest expense through June 30,	930,343
Balance at June 30,	3,222,167
Less: current portion	3,222,167
Convertible debt, long-term portion

Convertible Debt and Other De38

Convertible Debt and Other Debt - Schedule of Merchant Agreements (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Purchase Price	$ 1,255,000
Purchased Amount	1,694,690
Outstanding Balance	544,112
Deferred Finance Fees	$ 34,106
Merchant Agreements One [Member]
Inception Date	Sep. 29, 2017
Purchase Price	$ 75,000
Purchased Amount	102,000
Outstanding Balance
Daily Payment	$ 1,200
Interest Rate	15.00%
Deferred Finance Fees	$ 1,500
Merchant Agreements Two [Member]
Inception Date	Oct. 25, 2017
Purchase Price	$ 110,000
Purchased Amount	153,890
Outstanding Balance
Daily Payment	$ 1,539
Interest Rate	15.00%
Deferred Finance Fees	$ 8,800
Merchant Agreements Three [Member]
Inception Date	Dec. 7, 2017
Purchase Price	$ 160,000
Purchased Amount	212,800
Outstanding Balance
Daily Payment	$ 1,252
Interest Rate	25.00%
Deferred Finance Fees	$ 5,799
Merchant Agreements Four [Member]
Inception Date	Dec. 12, 2017
Purchase Price	$ 160,000
Purchased Amount	212,800
Outstanding Balance
Daily Payment	$ 1,252
Interest Rate	15.00%
Deferred Finance Fees	$ 5,258
Merchant Agreements Five [Member]
Inception Date	Feb. 27, 2018
Purchase Price	$ 110,000
Purchased Amount	147,400
Outstanding Balance
Daily Payment	$ 921
Interest Rate	25.00%
Deferred Finance Fees	$ 1,650
Merchant Agreements Six [Member]
Inception Date	Apr. 11, 2018
Purchase Price	$ 140,000
Purchased Amount	187,600
Outstanding Balance	96,503
Daily Payment	$ 1,275
Interest Rate	13.00%
Deferred Finance Fees	$ 2,800
Merchant Agreements Seven [Member]
Inception Date	May 11, 2018
Purchase Price	$ 180,000
Purchased Amount	243,000
Outstanding Balance	151,542
Daily Payment	$ 1,519
Interest Rate	25.00%
Deferred Finance Fees	$ 2,599
Merchant Agreements Eight [Member]
Inception Date	May 15, 2018
Purchase Price	$ 180,000
Purchased Amount	244,800
Outstanding Balance	156,067
Daily Payment	$ 1,530
Interest Rate	15.00%
Deferred Finance Fees	$ 3,600
Merchant Agreements Nine [Member]
Inception Date	Jun. 29, 2018
Purchase Price	$ 140,000
Purchased Amount	190,400
Outstanding Balance	140,000
Daily Payment	$ 1,269
Interest Rate	25.00%
Deferred Finance Fees	$ 2,100

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jun. 28, 2018	Jun. 26, 2018	Jun. 14, 2018	Jun. 11, 2018	Jun. 08, 2018	Jun. 04, 2018	Jun. 01, 2018	May 30, 2018	May 25, 2018	May 24, 2018	May 14, 2018	May 09, 2018	May 02, 2018	May 02, 2018	Apr. 25, 2018	Apr. 12, 2018	Apr. 02, 2018	Mar. 27, 2018	Mar. 14, 2018	Mar. 12, 2018	Feb. 12, 2018	Jan. 19, 2018	Mar. 21, 2017	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018	Feb. 15, 2018	Dec. 31, 2017	Nov. 29, 2015	Dec. 12, 2013
Convertible preferred stock, authorized																								1,000,000		1,000,000		1,000,000
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								1,000,000		1,000,000		1,000,000
Warrant to purchase shares of common stock				110,833
Warrant exercise price per share				$ 3.50
Debt converted of shares																										25,243
Debt conversion price per share																								$ 7.50		$ 7.50
Fair value of derivatives																								$ 7,037,424		$ 7,037,424
Adjusted value of beneficial conversion feature																										$ 10,532,291
Common stock, shares outstanding under the plan																								6,508,074		6,508,074		1,147,234
Estimated fair value of unvested stock options																										$ 249,107
Unvested stock options weighted average period																										1 year 5 months 12 days
Intrinsic value options outstanding																								$ 0		$ 0
Intrinsic value options outstanding, exercisable																								0		0
Intrinsic value warrant outstanding and exercisable																								2,700,000		2,700,000
Interest expenses debt																								157,908
Amortized of debt discount																										129,768
Unamortized debt discount																								547,582		547,582		$ 401,856
Fair value recorded as other charges				$ 340,257																				312,637		312,637
Warrants term				5 years
Warrant exercise price increase				$ 15
Warrant exercise price decrease				$ 3.50
Modification of debt				$ 10,236
Accredited Investor [Memeber]
Convertible debentures term																					8 months
Number of restricted stock issued during period																		3,500			3,500
Accredited Investor [Memeber] | September 30, 2018
Amortized of debt discount																										$ 7,200
Debenture Holders [Member]
Number of common stock shares issued, shares																										25,243
Interest expenses debt																										$ 95,121
Debenture Holders [Member] | Board of Directors [Member]
Number of common stock shares issued, shares																										1,092
Convertible Loan [Member] | Accredited Investor [Memeber]
Debt conversion price per share	$ 7.50	$ 7.50			$ 7.50			$ 7.50	$ 7.50	$ 7.50	$ 7.50	$ 7.50			$ 7.50	$ 7.50				$ 7.50	$ 7.50	$ 7.50
Interest expenses debt																					$ 7,800
Convertible debentures term	6 months	3 months	9 months		6 months	1 year		2 months	1 year	1 year	9 months	6 months			1 year	6 months				6 months	6 months	6 months
Proceeds from loan	$ 50,000	$ 150,000	$ 250,000		$ 50,000	$ 75,000		$ 150,000	$ 75,000	$ 50,000	$ 50,000	$ 250,000			$ 105,000	$ 100,000				$ 253,000	$ 100,000	$ 150,000
One-time interest percentage																					10.00%	10.00%
Original issue of discount percentage																						10.00%
Number of restricted stock issued during period	4,000	6,000	5,000		1,000	1,360		2,000	900	600	1,000	8,000			1,200	2,000				6,750	5,000	4,000
Unamortized debt discount	$ 10,518	$ 20,242	$ 17,573		$ 3,271	$ 3,869		$ 6,870	$ 3,112	$ 2,075	$ 3,704	$ 26,466			$ 4,590	$ 7,218				$ 28,722	$ 10,474	$ 12,267
Number of restricted stock issued during period, value																					18,274
Debt interest rate per annum	5.00%	5.00%	10.00%		15.00%	5.00%		8.00%	4.00%	4.00%	15.00%	10.00%			4.00%	15.00%
Debt issuance costs	$ 2,500	$ 7,500	$ 30,000		$ 12,500	$ 9,500		$ 12,000	$ 3,750	$ 2,500	$ 12,500	$ 62,500			$ 5,000	$ 24,000				53,000
Debt converted into common stock, percentage			65.00%			60.00%			60.00%	60.00%					60.00%
Convertible Loan [Member] | Lenders [Member]
Repayment of loans																					$ 50,000
Convertible Loan [Member] | Lender [Member]
Convertible debentures term																	1 year
Proceeds from loan																	$ 85,000
Number of restricted stock issued during period																	1,150
Number of restricted stock issued during period, value																	$ 5,183
Debt interest rate per annum																	5.00%
Non-Convertible Loan [Member]
Warrant to purchase shares of common stock				20,000
Debt converted principal amount				$ 50,000
Debt converted of shares				20
Convertible debentures term																			1 year
Proceeds from loan																			$ 50,000
Amortized of debt discount																										$ 7,500
Non-Convertible Loan [Member] | Accredited Investor [Memeber]
Number of common stock shares issued, shares																									9,500
Interest expenses debt																											$ 28,490
Proceeds from loan																							$ 170,000				$ 170,000
Original issue of discount percentage																							10.00%
Number of restricted stock issued during period																							5,667
Amortized of debt discount																							$ 35,079					$ 52,079
Unamortized debt discount																								$ 0		$ 0
Debt interest rate per annum																							10.00%
Non-Convertible Loan [Member] | Accredited Investor [Memeber] | September 30, 2018
Number of common stock shares issued, shares																							7,200
Convertible Loan One [Member] | Accredited Investor [Memeber]
Debt conversion price per share															$ 7.50
Convertible debentures term															1 year
Proceeds from loan															$ 105,000
Number of restricted stock issued during period															1,200
Unamortized debt discount															$ 4,590
Debt interest rate per annum															4.00%
Debt issuance costs															$ 5,000
Debt converted into common stock, percentage															60.00%
2005 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																								1,800,000		1,800,000
Common stock, shares outstanding under the plan																								35,605		35,605
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																								2,917,519		2,917,519				3,000,000
Common stock, shares outstanding under the plan																								81,925		81,925
2015 Nonqualified Stock Option Plan [Member]
Common stock reserved for stock option plan																													5,000,000
Common stock, shares outstanding under the plan																								129,937		129,937
Investor [Member]
Warrant to purchase shares of common stock				29,167
Warrant [Member]
Common stock, shares outstanding under the plan																								6,263,607		6,263,607		899,542
Warrants [Member]
Number of warrants shares issued																								5,195,400		5,195,400
Broker Warrants [Member]
Number of warrants shares issued																								11,000		11,000
Securities Purchase Agreement [Member]
Sale of stock													100
Sale of stock, amount													$ 250,000
Warrant to purchase shares of common stock													100,000	100,000
Warrant exercise price per share													$ 3.50	$ 3.50
Securities Purchase Agreement [Member] | New Warrant [Member]
Warrant to purchase shares of common stock							20,000						100,000	100,000
Warrant exercise price per share							$ 3.50						$ 3.50	$ 3.50
Letter Agreement [Member]
Debt converted principal amount				$ 742,134
Debt converted of shares				296.80
Letter Agreement [Member] | New Warrant [Member]
Warrant to purchase shares of common stock				296,800							2,448,200
Warrant exercise price per share				$ 3.50							$ 3.50
Letter Agreement [Member] | Warrant [Member]
Warrant exercise price per share				$ 3.50							3.50
Letter Agreements [Member] | Accredited Investor [Memeber]
Number of common stock shares issued, shares				110,833
Share issued price per shares				$ 2.50
Letter Agreements [Member] | New Warrant [Member]
Debt conversion price per share											$ 3.50
Series A Junior Participating Preferred Stock [Member]
Number of stock designated																								20,000		20,000
Series A Convertible Preferred Stock [Member]
Number of stock designated																								313,960		313,960
Series B Convertible Preferred Stock [Member]
Number of stock designated																								279,256		279,256
Series C Convertible Preferred Stock [Member]
Number of stock designated																								88,098		88,098
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								850		850		850
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								300		300		300
Number of stock designated																								850		850
Series E Convertible Preferred Stock [Member]
Number of stock designated																								500		500
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								240,000		240,000		240,000
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								80,570		80,570		80,570
Number of stock designated																								240,000		240,000
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								10,000		10,000		10,000
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								10,000		10,000		10,000
Number of stock designated																								10,000		10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								21		21		21
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								21		21		21
Number of stock designated																								21		21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								6,250		6,250		6,250
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								3,458		3,458		3,458
Number of stock designated																								6,250		6,250
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								15,000		15,000		15,000
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								6,880		6,880		6,880
Number of stock designated																								15,000		15,000
Series AA Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																								10,000		10,000		10,000
Convertible preferred stock, par value																								$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued																								5,195.4		5,195.4		0
Number of stock designated																								10,000		10,000
Debt converted principal amount																				$ 147,791						$ 12,688,634
Debt converted of shares																										5,075.40
Debt conversion price per share																				$ 2.50
Series AA Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]
Convertible preferred stock, par value													$ 0.01	$ 0.01
Sale of stock														100
Number of preferred stock issued upon conversion													1,000	1,000
Sale of stock, amount														$ 250,000
Cumulative dividend percentage														8.00%
Series AA Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Accredited Investor [Memeber]
Convertible preferred stock, par value							$ 0.01
Sale of stock							20
Number of preferred stock issued upon conversion							1,000
Sale of stock, amount							$ 50,000
Series AA Convertible Preferred Stock [Member] | Letter Agreement [Member]
Debt converted principal amount											$ 6,220,500
Debt converted of shares				2,200							2,448.20
Debt conversion price per share				$ 2.50							$ 2.50
Series AA Convertible Preferred Stock [Member] | Letter Agreements [Member]
Debt converted of shares											2,448.20
Debt conversion price per share											$ 2.50
Series AA Preferred Stock with Warrants [Member] | Loan Agreements [Member]
Deemed dividend additional paid in capital																								$ 5,113		$ 5,113
Series AA Units [Member]
Debt conversion price per share													$ 2.50	$ 2.50
Reduction in exercise price amount														$ 207,899

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Shares, Beginning balance	1,147,234
Shares, Granted	5,376,734
Shares, Exercised
Shares, Expired	(12,669)
Shares, Forfeited	(3,225)
Shares, Ending balance	6,508,074
Exercisable, Beginning balance	1,073,850
Exercisable, Ending balance	6,460,810
Warrant [Member]
Shares, Beginning balance	899,542
Shares, Granted	5,376,734
Shares, Exercised
Shares, Expired	(12,669)
Shares, Forfeited
Shares, Ending balance	6,263,607
Weighted average price per share, Beginning balance | $ / shares	$ 12.03
Weighted average price per share, Granted | $ / shares	3.50
Weighted average price per share, Exercised | $ / shares
Weighted average price per share, Expired | $ / shares	12
Weighted average price per share, Forfeited | $ / shares
Weighted average price per share, Ending balance | $ / shares	$ 3.58
Stock Option [Member]
Shares, Beginning balance	247,692
Shares, Granted
Shares, Exercised
Shares, Expired
Shares, Forfeited	(3,225)
Shares, Ending balance	244,467
Weighted average price per share, Beginning balance | $ / shares	$ 10.95
Weighted average price per share, Granted | $ / shares
Weighted average price per share, Exercised | $ / shares
Weighted average price per share, Expired | $ / shares
Weighted average price per share, Forfeited | $ / shares	16.04
Weighted average price per share, Ending balance | $ / shares	$ 10.88

Stockholders' Deficit - Sched41

Stockholders' Deficit - Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Exercise price range, lower range limit	$ 7.50
Exercise price range, upper range limit	$ 30
Options outstanding, number of options | shares	244,467
Options outstanding, weighted average remaining contractual life (years)	7 years 1 month 6 days
Options outstanding, weighted average exercise price	$ 10.88
Options exercisable, number of options | shares	197,203
Options exercisable, weighted average remaining contractual life (years)	6 years 9 months 18 days
Options exercisable, weighted average exercise price	$ 11.29
Exercise Price 1 [Member]
Exercise price range, lower range limit	7.50
Exercise price range, upper range limit	$ 11.99
Options outstanding, number of options | shares	133,024
Options outstanding, weighted average remaining contractual life (years)	7 years 9 months 18 days
Options outstanding, weighted average exercise price	$ 8.63
Options exercisable, number of options | shares	96,160
Options exercisable, weighted average remaining contractual life (years)	7 years 4 months 24 days
Options exercisable, weighted average exercise price	$ 8.72
Exercise Price 2 [Member]
Exercise price range, lower range limit	12
Exercise price range, upper range limit	$ 14.99
Options outstanding, number of options | shares	88,705
Options outstanding, weighted average remaining contractual life (years)	7 years 2 months 12 days
Options outstanding, weighted average exercise price	$ 12
Options exercisable, number of options | shares	78,305
Options exercisable, weighted average remaining contractual life (years)	7 years 2 months 12 days
Options exercisable, weighted average exercise price	$ 12
Exercise Price 3 [Member]
Exercise price range, lower range limit	15
Exercise price range, upper range limit	$ 17.99
Options outstanding, number of options | shares	5,879
Options outstanding, weighted average remaining contractual life (years)	4 years 2 months 12 days
Options outstanding, weighted average exercise price	$ 15
Options exercisable, number of options | shares	5,879
Options exercisable, weighted average remaining contractual life (years)	4 years 2 months 12 days
Options exercisable, weighted average exercise price	$ 15
Exercise Price 4 [Member]
Exercise price range, lower range limit	18
Exercise price range, upper range limit	$ 20.99
Options outstanding, number of options | shares	12,187
Options outstanding, weighted average remaining contractual life (years)	1 year 8 months 12 days
Options outstanding, weighted average exercise price	$ 18
Options exercisable, number of options | shares	12,187
Options exercisable, weighted average remaining contractual life (years)	1 year 8 months 12 days
Options exercisable, weighted average exercise price	$ 18
Exercise Price 5 [Member]
Exercise price range, lower range limit	21
Exercise price range, upper range limit	$ 30
Options outstanding, number of options | shares	4,672
Options outstanding, weighted average remaining contractual life (years)	2 years 4 months 24 days
Options outstanding, weighted average exercise price	$ 30
Options exercisable, number of options | shares	4,672
Options exercisable, weighted average remaining contractual life (years)	2 years 4 months 24 days
Options exercisable, weighted average exercise price	$ 30

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Aug. 08, 2018USD ($)$ / sharesshares	Aug. 02, 2018shares	Jul. 31, 2018USD ($)shares	Jul. 30, 2018USD ($)$ / shares	Jul. 27, 2018shares	Jul. 26, 2018shares	Jul. 19, 2018USD ($)shares	Jul. 18, 2018USD ($)$ / sharesshares	Jul. 18, 2018USD ($)$ / sharesshares	Jul. 17, 2018USD ($)$ / sharesshares	Jul. 16, 2018USD ($)$ / shares	Jul. 13, 2018USD ($)Integer	Jul. 10, 2018USD ($)Integer	Jul. 05, 2018USD ($)shares	Jul. 03, 2018USD ($)$ / sharesshares	Jul. 02, 2018USD ($)Integer$ / sharesshares	Jul. 01, 2018USD ($)shares	Jun. 28, 2018USD ($)$ / sharesshares	Jun. 26, 2018USD ($)$ / sharesshares	Jun. 14, 2018USD ($)shares	Jun. 08, 2018USD ($)$ / sharesshares	Jun. 04, 2018USD ($)shares	Jun. 01, 2018USD ($)shares	May 30, 2018USD ($)$ / sharesshares	May 25, 2018USD ($)$ / sharesshares	May 24, 2018USD ($)$ / sharesshares	May 14, 2018USD ($)$ / sharesshares	May 09, 2018USD ($)$ / sharesshares	May 02, 2018USD ($)$ / sharesshares	May 02, 2018USD ($)$ / sharesshares	Apr. 25, 2018USD ($)$ / sharesshares	Apr. 12, 2018USD ($)$ / sharesshares	Mar. 27, 2018shares	Mar. 12, 2018USD ($)$ / sharesshares	Feb. 12, 2018USD ($)$ / sharesshares	Jan. 19, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / shares	Jun. 30, 2018USD ($)$ / shares	Jun. 30, 2017USD ($)	Jun. 11, 2018$ / sharesshares	Dec. 31, 2017$ / shares
Debt conversion price per share | $ / shares																																					$ 7.50	$ 7.50
Debt instrument, fee																																					$ 34,106	$ 34,106
Common stock, par value | $ / shares																																					$ 0.01	$ 0.01			$ 0.01
Fair value of debt discount																																						$ 129,768
Warrant to purchase shares of common stock | shares																																								110,833
Warrant exercise price per share | $ / shares																																								$ 3.50
Interest expenses debt																																					$ 157,908
Stock option exercise price per shares | $ / shares																																					$ 10.88	$ 10.88
Debt principal amount																																					$ 4,029,750	$ 4,029,750
Series AA Convertible Preferred Stock [Member]
Debt conversion price per share | $ / shares																																		$ 2.50
Securities Purchase Agreement [Member]
Number of preferred stock sold | shares																													100
Number of preferred stock sold, amount																													$ 250,000
Warrant to purchase shares of common stock | shares																													100,000	100,000
Warrant exercise price per share | $ / shares																													$ 3.50	$ 3.50
Securities Purchase Agreement [Member] | Series AA Convertible Preferred Stock [Member]
Number of preferred stock sold | shares																														100
Preferred shares convertible to common stock | shares																													1,000	1,000
Number of preferred stock sold, amount																														$ 250,000
Securities Purchase Agreement [Member] | Series AA Convertible Preferred Stock [Member] | Accredited Investor [Memeber]
Number of preferred stock sold | shares																							20
Preferred shares convertible to common stock | shares																							1,000
Number of preferred stock sold, amount																							$ 50,000
Merchant Agreement [Member]
Fair value of debt discount																																						$ 55,811	$ 168,860
Subsequent Event [Member]
Number of restricted stock issued during period | shares		3
Debt interest rate per annum														5.00%
Convertible debentures term														1 year
Number shares issued for common stock | shares		3,154
Repayments of convertible loan														$ 95,000
Interest expenses debt								$ 13,125
Stock option exercise price per shares | $ / shares								$ 3.40	$ 3.40
Debt instrument expiration date									Jul. 18, 2028
Subsequent Event [Member] | Black Scholes Method [Member]
Common stock, shares available for future grant to employees | shares								58,000	58,000
Subsequent Event [Member] | Convertible Loan [Member]
Debt interest rate per annum												5.00%
Convertible debentures term												1 month
Monthly installments shares | shares					667	2,000
Repayments of convertible loan												$ 100,000
Subsequent Event [Member] | Convertible Loan [Member] | Accredited Investor [Memeber]
Number of restricted stock issued during period | shares	1,300						4,500
Number of restricted stock issued during period, value	$ 21,590
Debt interest rate per annum	15.00%			6.00%			10.00%
Convertible debentures term	6 months			1 year			1 year
Proceeds from loan	$ 100,000			$ 80,000			$ 150,000
Debt conversion price per share | $ / shares				$ 7.50
Debt conversion, percentage				60.00%
Debt instrument, fee	$ 23,500			$ 4,000
Fair value of debt discount							$ 15,350
Debt instrument expiration date	Feb. 8, 2019						Jan. 19, 2019
Interest paid							$ 36,000
Guaranteed interest percentage	5.00%
Subsequent Event [Member] | Convertible Loan One [Member] | Accredited Investor [Memeber]
Debt interest rate per annum												12.00%
Convertible debentures term												9 months
Proceeds from loan												$ 103,000
Debt conversion, percentage												42.00%
Debt conversion, trading days | Integer												15
Debt instrument, fee												$ 3,000
Subsequent Event [Member] | Convertible Loan Two [Member]
Number of restricted stock issued during period | shares										6,000
Number of restricted stock issued during period, value										$ 16,944
Monthly installments shares | shares										2,000
Subsequent Event [Member] | Convertible Loan Two [Member] | Accredited Investor [Memeber]
Number of restricted stock issued during period | shares										2,000
Debt interest rate per annum										15.00%
Convertible debentures term										3 months
Proceeds from loan										$ 100,000
Debt conversion price per share | $ / shares										$ 7.50
Subsequent Event [Member] | Convertible Note [Member]
Interest expenses debt								$ 131,250
Subsequent Event [Member] | Series AA Convertible Preferred Stock [Member] | Accredited Investor [Memeber]
Number of preferred stock sold | shares	52
Preferred shares convertible to common stock | shares	1,000
Common stock, par value | $ / shares	$ 0.01
Number of preferred stock sold, amount	$ 130,000
Warrant to purchase shares of common stock | shares	52,000
Warrant exercise price per share | $ / shares	$ 3.50
Subsequent Event [Member] | Six Month Agreement [Member]
Number of restricted stock issued during period | shares														24,000			24,000
Number of restricted stock issued during period, value														$ 79,920			$ 93,600
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Series AA Convertible Preferred Stock [Member]
Number of preferred stock sold | shares															148
Number of preferred stock sold, amount															$ 370,000
Subsequent Event [Member] | Merchant Agreement [Member]
Proceeds from loan											$ 180,000
Repayments of convertible loan											103,450
Subsequent Event [Member] | Merchant Agreement [Member] | Lender [Member]
Repayments of convertible loan											$ 246,600
Debt collected rate | $ / shares											$ 1,790
Interest expenses debt											$ 66,000
Guaranteed interest amount											$ 3,600
Subsequent Event [Member] | Warrant [Member] | Securities Purchase Agreement [Member]
Preferred shares convertible to common stock | shares															1,000
Common stock, par value | $ / shares															$ 0.01
Warrant to purchase shares of common stock | shares															148,000
Warrant exercise price per share | $ / shares															$ 3.50
Accredited Investor [Memeber]
Number of restricted stock issued during period | shares																																	3,500		3,500
Convertible debentures term																																			8 months
Accredited Investor [Memeber] | Convertible Loan [Member]
Number of restricted stock issued during period | shares																		4,000	6,000	5,000	1,000	1,360		2,000	900	600	1,000	8,000			1,200	2,000		6,750	5,000	4,000
Number of restricted stock issued during period, value																																			$ 18,274
Debt interest rate per annum																		5.00%	5.00%	10.00%	15.00%	5.00%		8.00%	4.00%	4.00%	15.00%	10.00%			4.00%	15.00%
Convertible debentures term																		6 months	3 months	9 months	6 months	1 year		2 months	1 year	1 year	9 months	6 months			1 year	6 months		6 months	6 months	6 months
Proceeds from loan																		$ 50,000	$ 150,000	$ 250,000	$ 50,000	$ 75,000		$ 150,000	$ 75,000	$ 50,000	$ 50,000	$ 250,000			$ 105,000	$ 100,000		$ 253,000	$ 100,000	$ 150,000
Debt conversion price per share | $ / shares																		$ 7.50	$ 7.50		$ 7.50			$ 7.50	$ 7.50	$ 7.50	$ 7.50	$ 7.50			$ 7.50	$ 7.50		$ 7.50	$ 7.50	$ 7.50
Debt conversion, percentage																				65.00%		60.00%			60.00%	60.00%					60.00%
Interest expenses debt																																			$ 7,800
Accredited Investor [Memeber] | Convertible Loan One [Member]
Number of restricted stock issued during period | shares																															1,200
Debt interest rate per annum																															4.00%
Convertible debentures term																															1 year
Proceeds from loan																															$ 105,000
Debt conversion price per share | $ / shares																															$ 7.50
Debt conversion, percentage																															60.00%
Accredited Investor [Memeber] | Subsequent Event [Member]
Number of restricted stock issued during period | shares			2,000
Number of restricted stock issued during period, value			$ 6,578
Debt interest rate per annum			8.00%										5.00%			4.00%
Convertible debentures term			2 months										1 year			1 year
Proceeds from loan			$ 150,000										$ 95,000			$ 125,000
Debt conversion price per share | $ / shares																$ 7.50
Debt conversion, percentage													40.00%			60.00%
Debt conversion, trading days | Integer													20			15
Debt instrument, fee			$ 12,000										$ 6,750			$ 6,250
Guaranteed interest percentage			12.00%
Accredited Investor [Memeber] | Subsequent Event [Member] | Common Stock [Member]
Number of restricted stock issued during period | shares																1,500
Number of restricted stock issued during period, value																$ 5,850
Board of Directors [Member] | Subsequent Event [Member]
Common stock, shares available for future grant to employees | shares								247,000	247,000
Stock based compensation awarded									$ 126,267